

Index

¹³C-octanoic breath test, 1341, 1481
¹³C-urea breath test, 553
4-aminosalicylic acid, 1771
5-aminosalicylic acid, 647, 207
5-HT₃ mechanisms, 225
5-HT₃ receptor antagonist, 119
5-HT₃ receptors, 1563
5-hydroxytryptamine, 623
6-mercaptopurine, 647
6-thioguanine nucleotides, 12-month course, 243

α -antagonist, 1801
 α -4 integrin, 699
 α -tocopherol, 985
abdominal irradiation, 623
Abe, H. *see* Murakami, K.
Abitbol, V., Mary, J.Y., Roux, C., Soulé, J.C., Belaiche, J., Dupas, J.-L., Gendre, J.P., Lerebours, E., Chaussade, S. & the Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID). Osteoporosis in inflammatory bowel disease: effect of calcium and vitamin D with or without fluoride, 919
absorption, 769
ABT-229, 749, 1481
acetaminophen, 707, 1539
acid, 303, 1469
acid inhibition, 425
acid secretion, 1723
acidity, 455
acute pancreatitis, 2097
Adachi, K., Ono, M., Kawamura, A., Yuki, M., Fujishiro, H. & Kinoshita, Y. Nizatidine and cisapride enhance salivary secretion in humans, 297
Adachi, K. *see* Hashimoto, T.
Adamo, S. *see* Rizzello, F.
Adams, G. *see* Malik, A.H.
adenosine triphosphate, 325
adjuvant chemotherapy, 353
adrenergic receptors, 1801
adverse effects, 27
Africa, 595
agents, 603
aging, 683
Ahmed, F. *see* Tutuian, R.
Ahn, D.S. *see* Choi, I.J.
Aichbichler, B. *see* Högenauer, C.
AIDS, 595, 799
Aisowmely, A.M. & Hodgson, H.J.F. Review article: non-surgical treatment of hepatocellular carcinoma, 1
Akamatsu, T. *see* Futagami, S.

Akkermans, L.M.A. *see* De Schryver, A.M.P.
Alampi, G. *see* Bazzoli, F.
albendazole, 595
alcohol, 497, 985
alimentary diseases, 1709
Allan, A. *see* Hulin, S.J.
allergies, 969
Allez, M. *see* Sabate, J.M.
alosetron, 225, 985
alverine citrate, 1187
amantadine, 2107
aminosalicylates, 79, 197
Amlot, P.L. *see* Gordon, F.H.
amoxicillin, 137, 793, 1163, 2067
ampicillin, 1163
amylose-ethylcellulose coating, 1771
anal anastomosis, 27
anal fissures, 101
Anderloni, A. *see* Parente, F.
Andreoli, A. *see* Armuzzi, A.
Andreu, V. *see* Calvet, X.
Andriesse, G.I. *see* De Schryver, A.M.P.
Andriulli, A. *see* Perri, F.
Andus, T. *see* Musch, E.
Annese, V. *see* Rizzello, F.
Annibale, B., Di Giulio, E., Caruana, P., Lahner, E., Capurso, G., Bordi, C. & Delle Fave, G. The long-term effects of cure of *Helicobacter pylori* infection on patients with atrophic body gastritis, 1723
Annibale, B. *see* Lahner, E.
Ansari, A., Hassan, C., Duley, J., Marinaki, A., Shobowale-Bakre, E.-M., Seed, P., Meenan, J., Yim, A. & Sanderson, J. Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease, 1743
antacids, 435, 2029
anterior cingulate cortex, 1357
Anthony, A. *see* Wakefield, A.J.
antibiotic prophylaxis, 727
antibiotic therapy, 1715
antibiotics, 291, 909, 1083, 1461
antibiotics resistance, 793
anticonvulsants, 1539
antidepressant, 1091
antidepressants, 1539
antigens, 533
antioxidants, 197, 1997
antisecretory agents, 1945
antisense, 1761
anti-TNF, 1101
Antoni, I. *see* Feydt-Schmidt, A.
antrum, 129

anxiety, 2081
APC2059, 407
 Appelman, S.A. *see* Huang, J.-Q.
appropriateness, 1443
 Aranha, G. *see* Avidan, B.
 Arguedas, M.R. *see* Thompson, B.F.
 Arita, T. *see* Murakami, K.
 Armuzzi, A., Candelli, M., Zocco, M.A., Andreoli, A., De Lorenzo, A., Nista, E.C., Miele, L., Cremonini, F., Cazzato, I.A., Grieco, A., Gasbarrini, G. & Gasbarrini, A. Review article: breath testing for human liver function assessment, 1977
 Arnott, I.D.R., Watts, D. & Ghosh, S. Review article: is clinical remission the optimum therapeutic goal in the treatment of Crohn's disease? 857
 Arnout, J. *see* Van Hecken, A.
 Arroyo, M.T. *see* Serrano, P.
 Artikis, V. *see* Georgopoulos, S.D.
 Asano, T. *see* Saitoh, T.
 Ascione, T. *see* Gaeta, G.B.
 Asgharian, B. *see* Bashir, S.
aspirin, 497, 929, 1945
 Athanasakis, E., Chrysos, E., Zoras, O.J., Tsiaoussis, J., Karkavitsas, N. & Xynos, E. Octreotide enhances the accelerating effect of erythromycin on gastric emptying in healthy subjects, 1563
 Atherton, J.C. *see* Stack, W.A.
atrophic body gastritis, 507, 1723
atrophic gastritis, 515
atrophy, 1923
atropic gastritis, 1449
atropine, 17
autoimmune disease, 1241
autoimmune gastritis, 281
 Avenhaus, W. *see* Ullerich, H.
 Avidan, B., Sonnenberg, A., Bhatia, H., Aranha, G., Schnell, T.G. & Sontag, S.J. Inguinal hernia is not a sign of colon cancer: results of a prospective screening trial, 1197
 Avidan, B., Sonnenberg, A., Schnell, T.G. & Sontag, S.J. There are no reliable symptoms for erosive oesophagitis and Barrett's oesophagus: endoscopic diagnosis is still essential, 735
 Axon, A. *see* Mallertheiner, P.
 Axon, A.T.R. *see* Mason, J.
 Ayub, K. *see* Verghese, V.J.
azathioprine, 79, 181, 389, 647, 1125, 1225, 1743, 1751, 2061
baclafen, 17, 869, 1655
 Bai, J.C. *see* Sambuelli, A.
 Baisley, K. *see* Warrington, S.
 Baj, M. *see* Sengupta, S.
 Bajador, E. *see* Lanas, A.
 Ball, D. *see* Shaw, I.S.
balsalazide, 6, 691
 Balzano, A. *see* Manes, G.
 Banna, N. *see* Langmead, L.
 Barabino, A., Torrente, F., Castellano, E., Gandullia, P., Calvi, A., Cucchiara, S., de'Angelis, G.L., Fontana, M., Lionetti, P., De Giacomo, C. & Gissi, A. The use of ciclosporin in paediatric inflammatory bowel disease: an Italian experience, 1503
 Barabino, A., Torrente, F., Ventura, A., Cucchiara, S., Castro, M. & Barbera, C. Azathioprine in paediatric inflammatory bowel disease: an Italian multicentre survey, 1125
 Barbera, C. *see* Barabino, A.
 Bargiggia, S. *see* Parente, F.
 Barish, C. *see* Sands, B.E.
 Barish, C. *see* Yacyshyn, B.R.
 Baron, J.H. & Sonnenberg, A. Alimentary diseases in the poor and middle class in London 1773–1815, and in New York poor 1797–1818, 1709
Barrett's oesophagus, 735, 887, 893, 1795
 Barth, J.A. *see* Gardner, J.D.
 Bartolozzi, F. *see* Cremonini, F.
 Bartolozzi, F. *see* Di Caro, S.
 Bashir, S., Cibril, F., Ojeaburu, J.V., Asgharian, B., Entsuah, L.K., Ferraro, G., Crafa, P., Bordi, C. & Jensen, R.T. Prospective study of the ability of histamine, serotonin or serum chromogranin A levels to identify gastric carcinoids in patients with gastrinomas, 1367
 Basit, A.W. *see* Tuleu, C.
 Basilisco, G. *see* Massironi, S.
 Bates, J. *see* Rubin, G.
 Bayerdörfler, E. *see* Mallertheiner, P.
 Bazzoli, F., Zagari, R.M., Pozzato, P., Fossi, S., Ricciardelli, L., Nicolini, G., De Luca, I., Berretti, D., Alampi, G., Di Pietro, C., Morelli, P. & Roda, E. Low-dose lansoprazole and clarithromycin plus metronidazole vs. full-dose lansoprazole and clarithromycin plus amoxicillin for eradication of *Helicobacter pylori* infection, 153
 Büchler, M.W. *see* Netzer, P.
beclometasone dipropionate, 1109
 Belaiche, J. *see* Abitbol, V.
 Bella, M.R. *see* Calvet, X.
 Benito, R. *see* Lanas, A.
 Benson, M.J. *see* Zar, S.
benzodiazepines, 361, 1539
 Bergenheim, K. *see* Vakil, N.
 Berman, S. *see* Mayer, E.A.
 Bermejo, F. *see* Boixeda, D.
 Bernal, I. *see* Domènech, E.
 Bernard, B. *see* Goulenok, C.
 Bernard, D. *see* Van Vlierberghe, H.
 Bernasconi, G. *see* Ortiz, R.A.M.
 Berretti, D. *see* Bazzoli, F.
beta-agonists, 1539
beta-antagonist, 1801
 Bhat, K., Harper, A. & Gorard, D.A. Perceived food and drug allergies in functional and organic gastrointestinal disorders, 969
 Bhatia, H. *see* Avidan, B.
 Biagini, R. *see* Bilardi, C.
 Biagini, R. *see* Zentilin, P.
 Bianchi Porro, G. *see* Parente, F.
 Bianchi Porro, G. *see* Stockbrügger, R.W.
bicarbonate, 297
 Biemond, I. *see* Kamerling, I.M.C.
bifidobacteria, 587, 1669

Bilardi, C. *see* Zentilin, P.
 Bilardi, C., Biagini, R., Dulbecco, P., Iritano, E., Gambaro, C., Mele, M.R., Borro, P., Tessieri, L., Zentilin, P., Mansi, C., Vigneri, S. & Savarino, V. Stool antigen assay (HpSA) is less reliable than urea breath test for post-treatment diagnosis of *Helicobacter pylori* infection, 1733
 Bilardi, C. *see* Zentilin, P.
biliary disease, 1037
biliary disorders, 1083
bioartificial liver, 1547
biologic response modifier, 399
biological agents, 1579
bisacodyl, 1327
bismuth, 1457
 Bjorkman, D. *see* El-Serag, H.B.
bleeding, 1137
 Bliesath, H. *see* Novick, J.
bloating, 225, 1867
 Blum, A.L. *see* Holtmann, G.
 Blumer, J.L. *see* Orenstein, S.R.
 Bochenek, W. *see* Kovacs, T.O.G.
 Bochenek, W. *see* Tutuian, R.
 Bode, G. *see* Rothenbacher, D.
 Boeckxstaens, G.E.E. *see* Hirsch, D.P.
 Boeckxstaens, G.E.E. *see* Kuiken, S.D.
 Boerr, I. *see* Sambuelli, A.
 Boesiger, P. *see* Faas, H.
 Bogers, J.J.P.M. *see* De Block, C.E.M.
 Boix, J. *see* Doménech, E.
 Boixeda, D., Bermudo, F., Martín-De-Argila, C., López-Sanromán, A., Deforges, V., Hernández-Ranz, F., Milicua, J.M. & García-Plaza, A. Efficacy of quadruple therapy with pantoprazole, bismuth, tetracycline and metronidazole as rescue treatment for *Helicobacter pylori* infection, 1457
 Bollani, S. *see* Stockbrügger, R.W.
 Bommelaer, G. *see* Hallerbäck, B.
 Bommelaer, G. *see* Marteau, P.
 Bonanno, G. *see* Caletti, G.
 Bondesen, S. *see* Schiødt, F.V.
bone, 919
bone mineral density, 1519, 1895
 Bonnet, J. *see* Sabate, J.M.
 Bordi, C. *see* Annibale, B.
 Bordi, C. *see* Bashir, S.
 Bordi, C. *see* Lahner, E.
 Borque, M.J. *see* Moreno-Monteagudo, J.A.
 Borrelli, O. *see* Franzese, A.
 Borro, P. *see* Bilardi, C.
 Tortolotti, M., Coccia, G., Grossi, G. & Miglioli, M. The treatment of functional dyspepsia with red pepper, 1075
 Bory, F. *see* Calvet, X.
 Botta, F. *see* Giannini, E.
 Bouley, C. *see* Marteau, P.
 Bouvier, A.-M. *see* Faivre-Finn, C.
 Bouvier, M. *see* Marteau, P.
bowel disorders, 1867
bowel habit, 759
 Boyce, M. *see* Warrington, S.
 Bozzola, L. *see* Fabris, P.
 Braden, B., Enghofer, M., Schaub, M., Usadel, K.-H., Caspary, W.F. & Lembecke, B. Long-term cisapride treatment improves diabetic gastroparesis but not glycaemic control, 1341
breath tests, 1571
 Bredberg, E. *see* Hallerbäck, B.
 Brenner, H. *see* Rothenbacher, D.
 Brinkhoff, H. *see* Chen, C.L.
 Brinkmann, B.H. *see* Kuo, B.
 Brouwers, J.R.B.J. *see* Klok, R.M.
 Brown, J. *see* Mason, J.
 Börsch, G. *see* Peitz, U.
 Brullet, E. *see* Calvet, X.
 Bruno, R. *see* Gaeta, G.B.
 Brzezinski, A. *see* Tremaine, W.J.
budesonide, 27
 Bujanda, L. *see* Elizalde, J.I.
 Burggraaf, J. *see* Kamerling, I.M.C.
 Burke, T.A. *see* Goldstein, J.L.
 Burman, C.-F. *see* Malfertheiner, P.
 Burton, D. *see* Kuo, B.
 Burton, D.D. *see* Cremonini, F.
 Buscarini, E. *see* Caletti, G.
 Buti, M. *see* San Miguel, R.
butyl scopolamine bromide, 111
butyrate, 325
 Bytzer, P. *see* Holtmann, G.
 Bytzer, P. *see* Madsen, L.G.

 C282Y, 1963
 Cabanne, A. *see* Sambuelli, A.
 Cabasés, J.M. *see* San Miguel, R.
 Cabré, E. *see* Doménech, E.
Caco-2, 1021
cadherin, 1059
 Cadranel, J.F. *see* Goulenok, C.
caesomorphine, 663
cagA, 1015
 Cahill, J. *see* Van Den Bogaerde, J.
 Calafatti, S.A. *see* Ortiz, R.A.M.
calcium, 919
 Caletti, G., Zinzani, P.L., Fusaroli, P., Buscarini, E., Parente, F., Federici, T., Peyre, S., De Angelis, C., Bonanno, G., Togliani, T., Pileri, S., Tura, S. & The Italian Gastric Lymphoma Study Group. The importance of endoscopic ultrasonography in the management of low-grade gastric mucosa-associated lymphoid tissue lymphoma, 1715
 Calvet, X., Ducons, J., Guardiola, J., Tito, L., Andreu, V., Bory, F., Guirao, R. & The Group for Eradication Studies from Catalonia, Aragón (GRESCA). One-week triple vs. quadruple therapy for *Helicobacter pylori* infection — a randomized trial, 1261
 Calvet, X., Sanfeliu, I., Musulen, E., Mas, P., Dalmau, B., Gil, M., Bella, M.R., Campo, R., Brullet, E., Valero, C. & Puig, J. Evaluation of *Helicobacter pylori* diagnostic methods in patients with liver cirrhosis, 1283
 Calvet, X. *see* Vallve, M.

Calvi, A. *see* Barabino, A.
 Calza, L. *see* Manfredi, R.
 Camartino, G. *see* Sambuelli, A.
 Camilleri, M., Heading, R.C. & Thompson, W.G. Consensus report: clinical perspectives, mechanisms, diagnosis and management of irritable bowel syndrome. 1407
 Camilleri, M. *see* Cremonini, F.
 Camilleri, M. *see* Kuo, B.
C-aminopyrine breath test. 717
 Cammarota, G. *see* Di Caro, S.
 Campanone, A. *see* Gaeta, G.B.
 Campbell, M. *see* Hallerbäck, B.
 Campbell, S., Kingstone, K. & Ghosh, S. Relevance of thiopurine methyltransferase activity in inflammatory bowel disease patients maintained on low-dose azathioprine. 389
 Campieri, M. *see* Mimura, T.
 Campieri, M. *see* Rizzello, F.
 Campo, R. *see* Calvet, X.
campylobacter. 1037
cancer registries. 353
cancer screening. 41
 Candelli, M. *see* Armuzzi, A.
 Candelli, M. *see* Di Caro, S.
 Cange, L., Johnsson, E., Rydholm, H., Lehmann, A., Finizia, C., Lundell, L. & Ruth, M. Baclofen-mediated gastro-oesophageal acid reflux control in patients with established reflux disease. 869
 Cann, P.A. *see* Mansfield, J.C.
 Capelli, G. *see* Cremonini, F.
 Caprilli, R., Viscido, A. & Guagnozzi, D. Review article: biological agents in the treatment of Crohn's disease. 1579
capsaicin. 1075
 Capurso, G. *see* Annibale, B.
 Caratto, E. *see* Zentilin, P.
carbon-labelled breath tests. 1977
carcinoma. 1
cardiovascular. 577
cardiovascular disease. 1945
cardiovascular prophylaxis. 497
carotenoids. 985
 Caruana, P. *see* Annibale, B.
 Caruana, P. *see* Lahner, E.
carvedilol. 373
case-control analysis. 975
case-control study. 497
case-crossover study. 875
 Casetti, T. *see* Rizzello, F.
 Caspary, W.P. *see* Braden, B.
 Castell, D.O. *see* Tutuian, R.
 Castellano, E. *see* Barabino, A.
 Castiella, A. *see* Elizalde, J.I.
 Castiglione, G.N. *see* Rizzello, F.
 Castro, A. *see* Moreno-Montegudo, J.A.
 Castro, M. *see* Barabino, A.
 Cazzato, I.A. *see* Armuzzi, A.
celecoxib. 819
cell division. 633
cell proliferation. 633
CEM cells. 1021
 Chan, A.O.O. *see* Wong, W.-M.
 Chan, C.K. *see* Hung, W.K.
 Chan, C.K. *see* Wong, W.-M.
 Chan, C.K. *see* Wong, W.M.
 Chan, C.K. *see* Xia, H.H.-X.
 Chan, F.K.L. *see* Wu, J.C.Y.
 Chan, F.K.L. *see* You, J.H.S.
 Chan, H.L.Y. *see* Cheng, A.S.L.
 Chan, K.A. *see* Chang, C.H.
 Chan, T.Y.K. *see* You, J.H.S.
 Chang, C.H., Chen, K.Y., Lai, M.Y. & Chan, K.A. Meta-analysis: ribavirin-induced haemolytic anaemia in patients with chronic hepatitis C. 1623
 Chang, C.S. *see* Poon, S.K.
 Chang, F.-Y. *see* Luo, J.-C.
 Chang, K.K. *see* Yee, Y.K.
 Chang, L. *see* Mayer, E.A.
 Chapman, M.A.S. *see* Hulin, S.J.
 Chapman, R.W. *see* Mitchell, S.A.
 Chasen, R. *see* Rex, D.K.
 Chaussade, S. *see* Abitbol, V.
 Chayama, K. *see* Ito, M.
 Chen, C.L., Orr, W.C., Verlinden, M.H., Dettmer, A., Brinkhoff, H., Riff, D., Schwartz, S., Soloway, R.D., Krause, R., Lanza, F. & Mack, R.J. Efficacy of a motilin receptor agonist (ABT-229) for the treatment of gastro-oesophageal reflux disease. 749
 Chen, C.-Y. *see* Luo, J.-C.
 Chen, G.H. *see* Poon, S.K.
 Chen, J.-H. *see* Sheu, B.-S.
 Chen, K.Y. *see* Chang, C.H.
 Chen, T.-K. *see* Liao, C.-C.
 Chen, W.H. *see* Wong, W.-M.
 Cheng, A.S.L., Chan, H.L.Y., Leung, N.W.Y., Liew, C.T., To, K.F., Lai, P.B.S. & Sung, J.J.Y. Expression of cyclooxygenase-2 in chronic hepatitis B and the effects of anti-viral therapy. 251
 Cheng, C.S. *see* Ng, F.H.
 Cheung, H.K.L. *see* Xia, H.H.-X.
 Chey, W.D. *see* Ladabaum, U.
 Chi, C.-H. *see* Sheu, B.-S.
 Chiang, T.-C. *see* Liao, C.-C.
 Chiarbonello, B. *see* Giannini, E.
children. 951, 1125, 1503, 1663, 2073
Chinese. 465, 521, 2037
 Chinn, D. *see* Rubin, G.
 Chiodo, F. *see* Manfredi, R.
 Chiu, Y.-L. *see* Huang, J.-Q.
 Choi, I.J., Jung, H.C., Choi, K.W., Kim, J.H., Ahn, D.S., Yang, U.S., Rew, J.S., Lee, S.I., Rhee, J.C., Sik Chung, I., Chung, J.M. & Hong, W.-S. Efficacy of low-dose clarithromycin triple therapy and tinidazole-containing triple therapy for *Helicobacter pylori* eradication. 145
 Choi, I.J. *see* Kim, J.S.
 Choi, K.W. *see* Choi, I.J.
cholesterol. 577
 Christensen, E. *see* Schiodt, F.V.

chromogranin A, 1367
 chronic, 1623, 1633
 chronic hepatitis B, 251
 chronic hepatitis C, 243, 1091, 1555
 chronic hepatitis, 717
 chronic liver disease, 361
 chronic pancreatitis, 2097
 Chrysos, E. *see* Athanasakis, E.
 Chung, J.M. *see* Choi, I.J.
ciclosporin, 181, 1021, 1503, 2061
 Ciociola, A.A. *see* Gardner, J.D.
 Ciociola, A.A. *see* Orenstein, S.R.
 Ciociola, A.A. *see* Robinson, M.
ciprofloxacin, 909
cirrhosis, 985
cisapride, 297, 743, 951, 1641
clarithromycin, 137, 145, 569, 793, 1047
clarithromycin resistance, 1933, 2073
Claversal Foam, 415
 Clemens, C.H.M., Samsom, M., Van Berge Henegouwen, G.P.,
 Fabri, M. & Smout, A.J.P.M. Effect of alosetron on left colonic
 motility in non-constipated patients with irritable bowel
 syndrome and healthy volunteers, 993
 Clinard, F. *see* Faivre-Finn, C.
clinical practice, 487
clinical remission, 1233
clinical trial, 1327
clonidine, 945
 Coakley, A.J. *see* Lamb, E.J.
 Coccia, G. *see* Bortolotti, M.
coeliac disease, 1333
 Cohen, A.F. *see* Kamerling, I.M.C.
 Cohen, R.D. The quality of life in patients with Crohn's disease,
 1603
 Colin, R. for the HEPYLOG Investigator Study Group. Duodenal
 ulcer healing with 1-week eradication triple therapy followed,
 or not, by anti-secretory treatment: a multicentre double-blind
 placebo-controlled trial, 1157
colitis, 181
 Colle, I. *see* Van Vlierberghe, H.
 Collings, K.L., Rodriguez-Stanley, S., Proskin, H.M., Robinson, M.
 & Miner Jr, P.B. Clinical effectiveness of a new antacid chewing
 gum on heartburn and oesophageal pH control, 2029
colon, 603
colon carcinoma, 353
colon transit, 1781
colonic delivery, 1771
colonic fluid absorption, 623
colonic motility, 623, 985
colonic transit constipation, 759
colonic transit time, 587
colonoscopy, 937, 1197, 1327
colorectal cancer, 333, 1197, 1225
combined treatment, 243
complementary therapy, 197
complications, 27, 1547
concanavalin-A, 633
 Conio, M. *see* Zentilin, P.
constipation, 1701
constipation, 603
contrast agent, 217
controlled trial, 27, 1649
 Cooney, R. *see* Sengupta, S.
 Corazzi, A. *see* Ortiz, R.A.M.
corpus gastritis, 887
 Corrado, G. *see* Franzese, A.
 Correa, P. *see* Rugge, M.
corticosteroids, 647, 1241, 1519, 1939
cortisol, 1021
 Cosme, A. *see* Elizalde, J.I.
cost analysis, 1529, 2089
cost-effectiveness, 1469
cost-effectiveness analysis, 41
cost-minimization analysis, 1491
costs, 1217
co-twin control analysis, 975
 Coulshed, D.S. *see* Esliek, G.D.
COX activity, 847
COX-2 inhibitor, 847
 Crafa, P. *see* Bashir, S.
 Cremonini, F., Di Caro, S., Nista, E.C., Bartolozzi, F., Capelli, G.,
 Gasbarrini, G. & Gasbarrini, A. Meta-analysis: the effect of
 probiotic administration on antibiotic-associated diarrhoea,
 1461
 Cremonini, F., Mullan, B.P., Camilleri, M., Burton, D.D. & Rank,
 M.R. Performance characteristics of scintigraphic transit
 measurements for studies of experimental therapies, 1781
 Cremonini, F. *see* Armuzzi, A.
 Cremonini, F. *see* Di Caro, S.
 Crispino, P. *see* Paoluzi, O.A.
 Crocellá, L. *see* Della Monica, P.
 Crocombe, W. *see* Mason, J.
Crohn's disease, 51, 79, 399, 693, 857, 919, 1101, 1117, 1225,
 1509, 1519, 1579, 1603, 1743, 1761, 1895, 1903
Cronkhite-Canada syndrome, 333
crypt branching, 633
crypt fission, 633
 Csef, H. *see* Kraus, M.R.
 Cucchiara, S. *see* Barabino, A.
 Cucchiara, S. *see* Franzese, A.
 Cuillerier, E. *see* Marteau, P.
 Cunliffe, R.N. & Scott, B.B. Review article: monitoring for drug
 side-effects in inflammatory bowel disease, 647
C-urea breath test, 787
 Curran, R. *see* Massironi, S.
cyclo-oxygenase, 847
cyclo-oxygenase-2, 251
cyclo-oxygenase-2 inhibitor, 2089
CYP2C19 extensive metabolizer, 1811
CYP2C19 genotype, 837
cytokines, 399
cytosolic hepatic function, 1977
 Dalhoff, K. *see* Schmidt, L.E.
 D'Alincourt, A. *see* Gournay, J.

Dalke, D. *see* Yacyshyn, B.R.
 Dalmau, B. *see* Calvet, X.
 D'Ambra, G. *see* Lahner, E.
 D'Arienzo, A. *see* Rizzello, F.
 Dawson, C. *see* Langmead, L.
 Day, A. *see* Shaw, I.S.
 De Angelis, C. *see* Caletti, G.
 De Argila, C.M. *see* Elizalde, J.I.
 De Block, C.E.M., De Leeuw, I.H., Bogers, J.J.P.M., Pelekmans, P.A., Ieven, M.M., Van Marck, E.A.E., Van Hoof, V., Måday, E., Van Acker, K.L. & Van Gaal, L.F. *Helicobacter pylori*, parietal cell antibodies and autoimmune gastropathy in type 1 diabetes mellitus. 281
 De Boer, W.A. *see* Laheij, R.J.F.
 De Giacomo, C. *see* Barabino, A.
 De Hoon, J.N. *see* Van Hecken, A.
 de Jong-van den Berg, L.T.W. *see* Klok, R.M.
 de Lalla, F. *see* Fabris, P.
 De Leeuw, I.H. *see* De Block, C.E.M.
 De Lepeleire, I. *see* Van Hecken, A.
 De Lorenzo, A. *see* Armuzzi, A.
 De Luca, I. *see* Bazzoli, F.
 De Micheli, E. *see* Frazzoni, M.
 De Pauw, M. *see* Sloots, C.E.J.
 De Pedro, A. *see* Moreno-Montegudo, J.A.
 De Ponti, F., Netzer, R., DeGiorgio, M.C., Bateson, H.K., Parsons, P. & Inauen, W. Letters to the Editors. 643
 De Schryver, A.M.P., Andriesse, G.J., Samsom, M., Smout, A.J.P.M., Gooszen, H.G. & Akkermans, L.M.A. The effects of the specific 5HT₄ receptor agonist, prucalopride, on colonic motility in healthy volunteers. 603
 De Sena, R. *see* Gaeta, G.B.
 De Souza, C.A.F. *see* Ortiz, R.A.M.
 De Vos, M. *see* Van Vlierberghe, H.
 de'Angelis, G.L. *see* Barabino, A.
decision analysis. 41, 727, 1003
decision tree. 2089
 Defarges, V. *see* Boixeda, D.
 Deguer, M. *see* Ortiz, R.A.M.
 Delanghe, J. *see* Van Vlierberghe, H.
 Della Monica, P., Lavagna, A., Masoero, G., Lombardo, L., Crocellà, L. & Pera, A. Effectiveness of *Helicobacter pylori* eradication treatments in a primary care setting in Italy. 1269
 Delle Fave, G. *see* Annibale, B.
 Delle Fave, G. *see* Lahner, E.
 Demetriou, A.A. *see* Pazzi, P.
 Dent, J. *see* Mallerttheiner, P.
 Dépré, M. *see* Van Hecken, A.
depression. 1091
 Derbyshire, S.W.G. *see* Mayer, E.A.
 Desager, J.P. *see* Dewit, O.
 Dettmer, A. *see* Chen, C.L.
 Devault, K. *see* Kovacs, T.O.G.
development. 799
 Dewit, O., Vanheuverzwyn, R., Desager, J.P. & Horsmans, Y. Interaction between azathioprine and aminosalicylates: an *in vivo* study in patients with Crohn's disease. 79
 Dhillon, A.P. *see* Gordon, F.H.
 Dhir, V. *see* Laine, L.
 Di Caro, S., Ojetti, V., Zocco, M.A., Cremonini, F., Bartolozzi, F., Candelli, M., Lupascu, A., Nista, E.C., Cammarota, G. & Gasbarrini, A. Mono, dual and triple moxifloxacin-based therapies for *Helicobacter pylori* eradication. 527
 Di Caro, S. *see* Cremonini, F.
 Di Giulio, E. *see* Annibale, B.
 Di Giulio, E. *see* Lahner, E.
 Di Martino, V. *see* Goulenok, C.
 Di Matteo, G. *see* Rizzello, F.
 Di Nardo, G. *see* Franzese, A.
 Di Pietro, C. *see* Bazzoli, F.
diabetes. 281, 951
diabetic gastropathy. 945
diagnosis. 683, 813, 1407, 1443
diagnosis and eradication. 533
diagnostic. 1283
diagnostic accuracy. 787
diarrhoea. 595, 769, 1461, 1709
diclofenac. 819
distal ulcerative colitis. 415
 Distrutti, E., Fiorucci, S., Hauer, S.K., Pensi, M.O., Vanasia, M. & Morelli, A. Effect of acute and chronic levosulpiride administration on gastric tone and perception in functional dyspepsia. 613
 Dito, L. *see* Franzese, A.
 Dixon, M.F. *see* Ruggie, M.
 Doldán, I. *see* Sambuelli, A.
 Domareva, I. *see* Isakov, V.
 Domènech, E., Garcia-Planella, E., Bernal, I., Rosinach, M., Cabré, E., Fluvia, L., Boix, J. & Gassull, M.A. Azathioprine without oral cyclosporin in the long-term maintenance of remission induced by intravenous cyclosporin in severe, steroid-refractory ulcerative colitis. 2061
domperidone. 951
 Domschke, W. *see* Ullerich, H.
 Donoghue, S. *see* Gordon, F.H.
 Dorn, G.H. *see* Ofman, J.J.
 Dorr, F.A. *see* Yacyshyn, B.R.
double blind. 27
 Draganov, V. *see* Tankova, L.
drug development. 343
drug interaction. 79, 1539
drug monitoring. 2053
drug therapy. 27
 Drummond, M. *see* Mason, J.
 Ducons, J. *see* Calvet, X.
 Duffett, S. *see* Mason, J.
 Dulbecco, P. *see* Bilardi, C.
 Dulbecco, P. *see* Zentilin, P.
 Duley, J. *see* Ansari, A.
duodenal disorders. 799, 1209, 1955
duodenal ulcer scar. 275
duodenal ulcer. 1137, 1157, 1431
duodenal ulcer. 275, 303, 779
 Dupas, B. *see* Gournay, J.

Dupas, J.-L. *see* Abitbol, V.
 Dwarakanath, A.D. *see* Rubin, G.
 DXA, 1519
 Dynder, A. *see* Van Hecken, A.
dysentery, 1709
dyspepsia, 105, 819, 1075, 1491, 1709, 2081
 Earnest, D.L. *see* Tougas, G.
 Ebert, M.P.A. & Malfertheiner, P. Review article: pathogenesis of sporadic and familial gastric cancer — implications for clinical management and cancer prevention, 1059
ECL cell hyperplasia, 1367
economic, 1217, 1469
effectiveness, 1269
 Eggo, M.C. *see* Hulin, S.J.
 Ehrenpreis, E.D. *see* Ginsburg, P.M.
 Eisen, G.M. *see* Goldstein, J.I.
elderly, 683
electrogastrography, 119, 129, 951
 Elizalde, I. *see* Elizalde, J.I.
 Elizalde, J.I., Piqué, J.M., Moreno, V., Morillas, J.D., Elizalde, I., Bujanda, L., De Argila, C.M., Cosme, A., Castiella, A. & Ros, E. (for the Group of Study of Oesophageal, Gastric Diseases from the Spanish Gastroenterological Association). Influence of *Helicobacter pylori* infection and eradication on blood lipids and fibrinogen, 577
 Ell, P.J. *see* Tuleu, C.
 Ellis, C. *see* Tinto, A.
 El-Serag, H.B., Olden, K. & Bjorkman, D. Health-related quality of life among persons with irritable bowel syndrome: a systematic review, 1171
 Emmanuel, A.V., Roy, A.J., Nicholls, T.J. & Kamm, M.A. Prucalopride, a systemic enterokinetic, for the treatment of constipation, 1347
 Emmanuel, A.V. *see* Van Den Bogaerde, J.
endoscopic ultrasonography, 1715
enema, 27
energy-deficiency, 325
 Enghofer, M. *see* Braden, B.
enteric-coated aspirin, 1683
enterokinetic, 603, 759
 Entsuah, L.K. *see* Bashir, S.
environmental factors, 975
epidemiology, 1407, 1519, 1709
epithelial transport, 1571
epithelium, 633
eradication, 153, 515, 1157, 1269, 1431, 1443, 1449, 1457, 2067
eradication treatment, 507
ERCP, 727
 Ernst, E. *see* Thompson Coon, J.
erosive oesophagitis, 445, 2043
erosive reflux oesophagitis, 735
erythromycin, 1563
 Eslick, G.D., Coulshed, D.S. & Talley, N.J. Review article: the burden of illness of non-cardiac chest pain, 1217
 Eslick, G.D., Yan, P., Xia, H.H.-X., Murray, H., Spurrett, B. & Talley, N.J. Foetal intrauterine growth restrictions with *Helicobacter pylori* infection, 1677
esomeprazole, 1301
essential fatty acids, 1125
 Evans, B.K. *see* Hawkes, N.D.
 Evans, J. *see* Huilgol, V.
 Evenepoel, P. *see* Geboes, K.P.
 Faas, H., Steingoetter, A., Feinle, C., Rades, T., Lengsfeld, H., Boesiger, P., Fried, M. & Schwizer, W. Effects of meal consistency and ingested fluid volume on the intragastric distribution of a drug model in humans—a magnetic resonance imaging study, 217
 Fabri, M. *see* Clemens, C.H.M.
 Fabris, P., Pilotto, A., Bozzola, L., Tositti, G., Sofliati, G., Manfrin, V. & de Lalla, F. Serum pepsinogen and gastrin levels in HIV-positive patients: relationship with CD4+ cell count and *Helicobacter pylori* infection, 807
faecal bile acids, 587
faecal markers, 675
 Faesssel, H.M. *see* Orenstein, S.R.
failure, 1047
 Faivre, J. *see* Faivre-Finn, C.
 Faivre-Finn, C., Bouvier, A.-M., Mitry, E., Rassiat, E., Clinard, F. & Faivre, J. Chemotherapy for colon cancer in a well-defined French population: is it under- or over-prescribed? 353
 Falasco, G., Zinicola, R. & Forbes, A. Review article: immunosuppressants in distal ulcerative colitis, 181
 Falk, P. *see* Hart, A.L.
 Faller, H. *see* Kraus, M.R.
familial, 1059
famotidine, 837, 1317
 Farrell, R.J., Menconi, M.J., Keates, A.C. & Kelly, C.P. P-Glycoprotein-170 inhibition significantly reduces cortisol and cyclosporin efflux from human intestinal epithelial cells and T lymphocytes, 1021
 Farthing, M.J.G. *see* Zulu, I.
 Fasciolo, D. *see* Zentilin, P.
 Fasoli, A. *see* Giannini, E.
 Fass, R. *see* Ofman, J.J.
 FAST trial investigation *see* Robinson, M.
 Feagan, B.G. *see* Kane, S.V.
 Feakins, R. *see* Zulu, I.
 Federici, T. *see* Caletti, G.
 Feinle, C. *see* Faas, H.
 Felaco, F.M. *see* Gaeta, G.B.
 Felsenberg, D. *see* Stockbrügger, R.W.
 Felt-Bersma, R.J.F. *see* Sloots, C.E.J.
 Feltbower, R. *see* Mason, J.
female, 1877
 Fendrick, A.M. *see* Ladabaum, U.
 Fennerty, M.B. *see* Ofman, J.J.
 Ferguson, A. *see* Stockbrügger, R.W.
fermented milk, 587
 Fernández-Bermejo, M. *see* Moreno-Monteagudo, J.A.
 Ferraro, G. *see* Bashir, S.
 Ferraz, J.G.P. *see* Ortiz, R.A.M.
 Ferreira, I.J. *see* Serrano, P.
 Fevery, J. *see* Van De Castele, M.

Feydt-Schmidt, A., Rüssmann, H., Lehn, N., Fischer, A., Antoni, I., Störk, D. & Koletzko, S. Fluorescence *in situ* hybridization vs. epsiloniometer test for detection of clarithromycin-susceptible and clarithromycin-resistant *Helicobacter pylori* strains in gastric biopsies from children, 2073

fibrinogen, 577

fibrosis, 717

Filice, G. *see* Gaeta, G.B.

Finizia, C. *see* Cange, L.

Fiocca, R. *see* Rugge, M.

Fioramonti, J. *see* Picard, C.

Fiorucci, S. *see* Distrutti, E.

Fischer, A. *see* Feydt-Schmidt, A.

FitzGerald, A.J. *see* Sasaki, M.

Fitzgerald, L. *see* Mayer, E.A.

Fitzgerald, S. *see* Robinson, M.

Fleming, T.J. *see* Tremaine, W.J.

flexible sigmoidoscopy, 1197

Flockhart, D.A. *see* Marino, G.

Floyd, D. *see* Khan, Z.

flunazenil, 361

fluorescence, 875

fluorescence *in-situ* hybridization, 2073

fluoride, 919

fluoroquinolones, 527

Fluvià, L. *see* Domènech, E.

foam enema, 415

foetal intrauterine growth restriction, 1677

Fontana, M. *see* Barabino, A.

food allergens, 1903

for the HEPYLOG Investigator Study Group. *see* Colin, R.

Forbes, A. *see* Falasco, G.

Ford, J. *see* Shaw, I.S.

Fordtran, J. *see* Högenauer, C.

Forman, D. *see* Mason, J.

Fossi, S. *see* Bazzoli, F.

Foster, R. *see* Poullis, A.

fractures, 1519

Frame, M. *see* Hart, A.L.

Franzese, A., Borrelli, O., Corrado, G., Rea, P., Di Nardo, G., Grandinetti, A.L., Dito, L. & Cucchiara, S. Domperidone is more effective than cisapride in children with diabetic gastroparesis, 951

Fraser, A.G., Morton, D., McGovern, D., Travis, S. & Jewell, D.P. The efficacy of methotrexate for maintaining remission in inflammatory bowel disease, 693

Fraser, A.G., Orchard, T.R., Robinson, E.M. & Jewell, D.P. Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine, 1225

Frazzoni, M., De Micheli, E., Grisendi, A. & Savarino, V. Hiatal hernia is the key factor determining the lansoprazole dosage required for effective intra-oesophageal acid suppression, 881

Frazzoni, M., De Micheli, E., Grisendi, A. & Savarino, V. Lansoprazole vs. omeprazole for gastro-oesophageal reflux disease: a pH-metric comparison, 35

Freyne, P.J. *see* Mahmud, N.

Fried, M. *see* Faas, H.

Fuentes, J. *see* Lanas, A.

Fujioka, T. *see* Murakami, K.

Fujishiro, H. *see* Adachi, K.

Fukushima, Y. *see* Saitoh, T.

Fumagalli, A. *see* Giannini, E.

functional constipation, 1347

functional dyspepsia, 613, 959, 1641, 1805

Fung, F.M.Y. *see* Hung, W.K.

Fung, F.M.Y. *see* Wong, W.M.

Fung, F.M.Y. *see* Xia, H.H.-X.

Fung, K. *see* Orenstein, S.R.

Fung, K. *see* Robinson, M.

furazolidone, 1277

Furuta, T., Shirai, N., Xiao, F., Takashima, M. & Hanai, H. Effect of *Helicobacter pylori* infection and its eradication on nutrition, 799

Furuta, T. *see* Shirai, N.

Fusaroli, P. *see* Caletti, G.

Futagami, S., Hiratsuka, T., Wada, K., Tatsuguchi, A., Tsukui, T., Miyake, K., Akamatsu, T., Hosone, M., Sakamoto, C. & Kobayashi, M. Inhibition of *Helicobacter pylori*-induced cyclooxygenase-2 aggravates NSAID-caused gastric damage in Mongolian gerbils, 847

GABA_B, 869

gabexate mesilate, 1791

Gaeta, G.B., Precone, D.F., Felaco, F.M., Bruno, R., Spadaro, A., Stornaiuolo, G., Stanzione, M., Ascione, T., De Sena, R., Campanone, A., Filice, G. & Piccinino, F. Premature discontinuation of interferon plus ribavirin for adverse effects: a multicentre survey in 'real world' patients with chronic hepatitis C, 1633

Gaia, C. *see* Netzer, P.

gallbladder, 129

gallbladder volume, 1801

Galmiche, J.P. *see* Gournay, J.

Gambaro, C. *see* Bilardi, C.

Gambaro, C. *see* Zentilin, P.

gamma scintigraphy, 1771

Gandullia, P. *see* Barabino, A.

Ganskaya, Z. *see* Isakov, V.

García-Buey, L. *see* Moreno-Monteagudo, J.A.

García-Plaza, A. *see* Boixeda, D.

Garcia-Planella, E. *see* Domènech, E.

Gardner, J.D., Ciociola, A.A., Robinson, M. & McIsaac, R.L. Determination of the time of onset of action of ranitidine and famotidine on intra-gastric acidity, 1317

Gardner, J.D., Perdomo, C., Sloan, S., Hahne, W.F., Barth, J.A., Rodriguez-Stanley, S. & Robinson, M. Integrated acidity and rabeprazole pharmacology, 455

Gardner, J.D., Rodriguez-Stanley, S., Robinson, M. & Miner Jr, P.B. Cisapride inhibits meal-stimulated gastric acid secretion and post-prandial gastric acidity in subjects with gastro-oesophageal reflux disease, 1819

gas, 1641

Gasbarrini, A. *see* Armuzzi, A.

Gasbarrini, A. *see* Cremonini, F.

Gasbarrini, A. *see* Di Caro, S.

Gasbarrini, G. *see* Armuzzi, A.
 Gasbarrini, G. *see* Cremonini, F.
 Gaspari, M. *see* Yacyshyn, B.R.
 Gasperi, V. *see* Perri, F.
 Gassull, M.A. *see* Domènech, E.
gastric, 799
gastric acidity, 875
gastric cancer, 1059
gastric carcinoid, 1367
gastric disorder, 1209, 1955
gastric emptying, 119, 945, 1341, 1481, 1563
gastric mucosal atrophy, 1249
gastric outlet obstruction, 1203
gastric perception, 613
gastric pH, 875
gastric ulcer, 779, 1137, 1431
gastric ultrasound, 951
gastrin, 303, 799, 1723, 1805
gastritis, 159
gastritis, 1923
gastroduodenal motility, 1563
gastrointestinal, 1059, 1781
gastrointestinal bleeding, 779, 2037
gastrointestinal disorders, 969
gastrointestinal endoscopy, 1003
gastrointestinal haemorrhage, 1945
gastrointestinal haemostasis, 1003
gastrointestinal hormones, 119
gastrointestinal oncology, 1197
gastrointestinal oncology, 1209, 1843
gastrointestinal tract, 633
gastro-oesophageal reflux disease, 17, 261, 435, 473, 479, 545, 735, 743, 749, 819, 869, 899, 1143, 1309, 1469, 1481, 1655, 1795, 2029, 2043
gastroparesis, 1341
gastroscopy, 1011
 Gatta, L. *see* Palli, D.
 Gavin, M.W. *see* Sonnenberg, A.
 Geboes, K.P., Maes, B., Luypaerts, A., Evenepoel, P., Rutgeerts, P., Ghoos, Y. & Geypens, B. Magnesium chloride slows gastric emptying, but does not affect digestive functions, 1571
 Geis, G.S. *see* Goldstein, J.L.
 Gendre, J.P. *see* Abitbol, V.
gene, 1059
general practice, 1067
genetic and familial-environmental effects, 975
genetic counselling, 1843
genetic testing, 1843
 Genta, R.M. *see* Rugege, M.
 Georgopoulos, S.D., Ladas, S.D., Karatapanis, S., Triantafyllou, K., Spiliadi, C., Mentis, A., Artikis, V. & Raptis, S.A. Effectiveness of two quadruple, tetracycline- or clarithromycin-containing, second-line, *Helicobacter pylori* eradication therapies, 569
 Gerhardt, M.F. *see* Marteau, P.
 Gertz, B. *see* Malchow, H.
 Geypens, B. *see* Geboes, K.P.
 Ghatei, M.A. *see* Sasaki, M.
 Ghoos, Y. *see* Geboes, K.P.
 Ghosh, S. *see* Arnott, I.D.R.
 Ghosh, S. *see* Campbell, S.
 Ghosh, S. *see* Khan, Z.
 Giaffer, M.H. *see* Mansfield, J.C.
 Giannini, E., Fasoli, A., Chiaronello, B., Malfatti, F., Romagnoli, P., Botta, F., Testa, E., Polegato, S., Fumagalli, A. & Testa, R. ¹¹C-Aminopyrine breath test to evaluate severity of disease in patients with chronic hepatitis C virus infection, 717
 Giardiello, F.M. *see* Trimbath, J.D.
 Gibril, F. *see* Bashir, S.
 Gibson, J.A. *see* Green, J.R.B.
 Gil, A. *see* Sambuelli, A.
 Gil, M. *see* Calvet, X.
 Ginsburg, P.M. & Ehrenpreis, E.D. A pilot study of thalidomide for patients with symptomatic mesenteric panniculitis, 2115
 Gionchetti, P. *see* Mimura, T.
 Gionchetti, P. *see* Rizzello, F.
 Gisbert, J.P. *see* Vallve, M.
 Gisbert, J.P. & Pajares, J.M. Review article: *Helicobacter pylori* 'rescue' regimen when proton pump inhibitor-based triple therapies fail, 1047
 Gisbert, J.P. & Pajares, J.M. Review article: *Helicobacter pylori* infection and gastric outlet obstruction — prevalence of the infection and role of antimicrobial treatment, 1203
 Gissi, A. *see* Barabino, A.
 Glebas, K. *see* Novick, J.
glidomorphine, 663
 Glise, H. *see* Hart, A.L.
glucagons, 111
gluten-free diet, 1333
 Goff, J. *see* Yacyshyn, B.R.
 Goldstein, J.L., Eisen, G.M., Burke, T.A., Peña, B.M., Lefkowitz, J., & Geis, G.S. Dyspepsia tolerability from the patients' perspective: a comparison of celecoxib with diclofenac, 819
 Goldwater, D.R. *see* Huang, J.-Q.
 Gonzalez, O. *see* Sambuelli, A.
 Goodlad, R.A. *see* Sasaki, M.
 Gooszen, H.G. *see* De Schryver, A.M.P.
 Gorard, D.A. *see* Bhat, K.
 Gordon, F.H., Hamilton, M.I., Donoghue, S., Greenlees, C., Palmer, T., Rowley-Jones, D., Dhillon, A.P., Amlot, P.L. & Pounder, R.E. A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin, 699
 Gottesdiener, K. *see* Van Hecken, A.
 Goulenok, C., Bernard, B., Cadanel, J.F., Thabut, D., Di Martino, V., Opolon, P. & Poynard, T. Flumazenil vs. placebo in hepatic encephalopathy in patients with cirrhosis: a meta-analysis, 361
 Gournay, J., Tchuenbou, J., Richou, C., Masliah, C., Lerat, F., Dupas, B., Martin, T., Nouel, J.F., Schnie, M., Montigny, P., D'Alincourt, A., Hamy, A., Paineau, J., Le Néel, J.-C., Le Borgne, J. & Galmiche, J.P. Percutaneous ethanol injection vs. resection in patients with small single hepatocellular carcinoma: a retrospective case-control study with cost analysis, 1529
 Graffner, H. *see* Hart, A.L.
 Graffner, H. *see* Stockbrügger, R.W.

Graham, D.Y. *see* Malferttheiner, P.
 Graham, D.Y. *see* Vergheese, V.J.
 Granato, A. *see* Pazzi, P.
 Grandinetti, A.L. *see* Franzese, A.
granisetron, 623
 Grant, C. *see* Hallert, C.
 Grant, G. *see* Sasaki, M.
 Graziano, A. *see* Sambuelli, A.
 Green, J.R.B., Mansfield, J.C., Gibson, J.A., Kerr, G.D. & Thornton, P.C. A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3 g daily, in patients with newly diagnosed or relapsed active ulcerative colitis. 61
 Green, L. *see* Rubin, G.
 Greenlees, C. *see* Gordon, F.H.
 Grehn, S. *see* Hallert, C.
 Grieco, A. *see* Armuzzi, A.
 Griffiths, N.M. *see* Picard, C.
 Grimaud, J.C. *see* Marteau, P.
 Grisendi, A. *see* Frazzoni, M.
 Grännö, C. *see* Hallert, C.
 Grossi, C. *see* Lahner, E.
 Grossi, G. *see* Bortolotti, M.
 Group of Study of Oesophageal, Gastric Diseases from the Spanish Gastroenterological Association, *see* Elizalde, J.I.
growth, 799
growth factors, 1917
growth retardation, 1677
 Grunow, J.E. *see* Orenstein, S.R.
 Gschossmann, J. *see* Holtmann, G.
 Gu, Q. *see* Wong, W.M.
 Guagnazzi, D. *see* Caprilli, R.
 Guardiola, J. *see* Calvet, X.
 Guillén, F. *see* San Miguel, R.
 Guirao, R. *see* Calvet, X.
gut flora, 1383
gut inflammation, 2017
gut transit, 1347
H₂-receptor antagonists, 1137, 1805
 Haapiainen, R. *see* Kokkola, A.
haemochromatosis, 1963
 Hahne, W.F. *see* Gardner, J.D.
 Hallerbäck, B., Bommelaer, G., Bredberg, E., Campbell, M., Hellblom, M., Lauritsen, K., Wienbeck, M. & Holmgren, L.-L. Dose finding study of mosapride in functional dyspepsia: a placebo-controlled, randomized study. 959
 Hallert, C., Grant, C., Grehn, S., Grännö, C., Hultén, S., Midhagen, G., Ström, M., Svensson, H. & Valdimarsson, T. Evidence of poor vitamin status in coeliac patients on a gluten-free diet for 10 years. 1333
 Hamelin, B. *see* Svedberg, P.
 Hamilton, M.I. *see* Gordon, F.H.
 Hamm, L. *see* Mayer, E.A.
 Hamy, A. *see* Gournay, J.
 Hanai, H. *see* Furuta, T.
 Hanai, H. *see* Shirai, N.
 Hanauer, S.B. *see* Sytgat, G.N.J.
 Harper, A. *see* Bhat, K.
 Hart, A. & Kamm, M.A. Review article: mechanisms of initiation and perpetuation of gut inflammation by stress. 2017
 Hart, A.L., Stagg, A.J., Frame, M., Graffner, H., Glise, H., Falk, P. & Kamm, M.A. Review article: the role of the gut flora in health and disease, and its modification as therapy. 1383
 Haruma, K. *see* Ito, M.
 Hashimoto, T., Adachi, K., Ishimura, N., Hirakawa, K., Katsume, T., Kurotani, A., Hattori, S. & Kinoshita, Y. Safety and efficacy of glucagon as a premedication for upper gastrointestinal endoscopy—a comparative study with butyl scopolamine bromide. 111
 Hassan, C. *see* Ansari, A.
 Hattori, S. *see* Hashimoto, T.
 Hattori, T. *see* Rugge, M.
 Hauer, S.K. *see* Distrutti, E.
 Hawkes, N.D., Rhodes, J., Evans, B.K., Rhodes, P., Hawthorne, A.B. & Thomas, G.A.O. Naloxone treatment for irritable bowel syndrome—a randomized controlled trial with an oral formulation. 1649
 Hawkey, C.J. *see* Stack, W.A.
 Hawkey, G.M. *see* Stack, W.A.
 Hawkins, C. *see* Langmead, L.
 Hawthorne, A.B. *see* Hawkes, N.D.
 Hayashi, P.H. & Trotter, J.F. Review article: adult-to-adult right hepatic lobe living donor liver transplantation. 1833
 Hayes, P.C. *see* Tripathi, D.
 Heading, R.C. *see* Camilleri, M.
healing, 1157
health, 1469
health economics, 559
health status, 1101
health-care seeking behaviour, 1217
health-related quality of life, 1101
health-seeking behaviour, 2081
healthy volunteers, 819
 Hearing, S.D. *see* Shaw, I.S.
heartburn, 435, 479, 899, 1309, 1431, 1819, 2029
 Hegedus, R. *see* Robinson, M.
Helicobacter pylori therapy, 1143
Helicobacter pylori, 105, 137, 145, 153, 159, 167, 275, 281, 291, 315, 487, 497, 507, 515, 521, 527, 533, 545, 559, 569, 577, 683, 779, 787, 793, 799, 813, 847, 887, 1015, 1037, 1047, 1059, 1143, 1149, 1163, 1203, 1241, 1261, 1269, 1277, 1283, 1291, 1301, 1431, 1443, 1449, 1457, 1663, 1677, 1669, 1715, 1723, 1733, 1805, 1933, 2067, 2073
Hellblom, M. *see* Hallerbäck, B.
 Hellman, R.S. *see* Huilgol, V.
 Helwig, U. *see* Mimura, T.
hepatopoietin, 235
hepatic encephalopathy, 361
hepatic resection, 1529
hepatic venous pressure gradient, 373
hepatitis C virus, 717
hepatitis C, 381, 1611, 1623, 1633, 2107
hepatocellular, 1
hepatocellular carcinoma, 251, 1529

hepatocyte growth factor, 235

herbal medicine, 1689

herbal therapies, 197

hereditary, 1059

hereditary colorectal cancer, 1843

Hernández-Ranz, F. *see* Boixeda, D.

HFE, 1963

Högenauer, C., Aichbichler, B., Santa Ana, C., Porter, J. & Fordtran, J. Effect of octreotide on fluid absorption and secretion by the normal human jejunum and ileum *in vivo*, 769

HHC, 1963

hiatal hernia, 881

high amplitude propagated contraction, 985

Higham, J. *see* Kang, J.-Y.

high-dose interferon- α , 2107

highly active antiretroviral therapy (HAART), 1791

Hirakawa, J. *see* Saitoh, T.

Hirakawa, K. *see* Hashimoto, T.

Hiratsuka, T. *see* Futagami, S.

Hirohata, Y. *see* Yoshikawa, I.

Hirsch, D.P., Tytgat, G.N.J. & Boeckxstaens, G.E.E. Review article: transient lower oesophageal sphincter relaxations—a pharmacological target for gastro-oesophageal reflux disease? 17

Hirschowitz, B.I., Simmons, J. & Mohnen, J. Minor effects of *Helicobacter pylori* on gastric secretion and dose of lansoprazole during long-term treatment in ZE and non-ZE acid hypersecretors, 303

histamine 2 receptor antagonists, 473

histamine-metabolite, 1367

HIV, 799

HIV infection, 1791

Ho, V.Y.K. *see* Hung, W.K.

Hodgson, H.J.F. *see* Aisowmely, A.M.

Hofer, T. *see* Kane, S.V.

Hojo, M., Miwa, H., Ohkusa, T., Ohkura, R., Kurosawa, A. & Sato, N. Alteration of histological gastritis after cure of *Helicobacter pylori* infection, 1923

Holdsworth, C.D. *see* Mansfield, J.C.

Holman, R. *see* Kuiken, S.D.

Holmgren, L.-L. *see* Hallerbäck, B.

Holt, M.P. *see* Khan, Z.

Holtmann, G., Bytzer, P., Metz, M., Loewler, V. & Blum, A.L. A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease, 479

Holtmann, G., Gschossmann, J., Mayr, P. & Talley, N.J. A randomized placebo-controlled trial of simethicone and cisapride for the treatment of patients with functional dyspepsia, 1641

Holton, J. *see* Palli, D.

homocysteine, 1333

Hong, W.-S. *see* Choi, I.J.

Horsmans, Y. *see* Dewit, O.

Hosone, M. *see* Futagami, S.

hospital admissions, 2097

Howden, C.W. *see* Levine, J.E.

HPO, 235

HpSA, 1733

Härkönen, M. *see* Kokkola, A.

Hu, W.H.C., Wong, W.-M., Lam, C.L.K., Lam, K.F., Hui, W.M., Lai, K.C., Xia, H.X.H., Lam, S.K. & Wong, B.C.Y. Anxiety but not depression determines health care-seeking behaviour in Chinese patients with dyspepsia and irritable bowel syndrome: a population-based study, 2081

Hu, W.H.C. *see* Hung, W.K.

Hu, W.H.C. *see* Wong, W.-M.

Hu, W.H.C. *see* Wong, W.M.

Hu, W.H.C. *see* Xia, H.H.-X.

Huang, C.-C. *see* Sheu, B.-S.

Huang, J.-Q., Goldwater, D.R., Thomson, A.B.R., Appelman, S.A., Sridhar, S., James, C.F., Chiu, Y.-L., Pilmer, B.L., Keith, R.G. & Hunt, R.H. Acid suppression in healthy subjects following lansoprazole or pantoprazole, 425

Huang, S.-H. *see* Liao, C.-C.

Huernos, S. *see* Sambuelli, A.

Hui, C.-K., Lai, K.-C., Yuen, M.-F., Wong, W.-M., Lam, S.-K. & Lai, C.-L. Does withholding aspirin for one week reduce the risk of post-sphincterotomy bleeding? 929

Hui, C.K. *see* Wong, W.-M.

Hui, W.M. *see* Hu, W.H.C.

Hui, W.M. *see* Wong, W.-M.

Huilgol, V., Evans, J., Hellman, R.S. & Soergel, K.H. Acute effect of clonidine on gastric emptying in patients with diabetic gastropathy and controls, 945

Hulin, S.J., Singh, S., Chapman, M.A.S., Allan, A., Langman, M.J.S. & Eggo, M.C. Sulphide-induced energy deficiency in colonic cells is prevented by glucose but not by butyrate, 325

Hultén, S. *see* Hallert, C.

Hung, W.K., Wong, W.M., Wong, G.S.W., Yip, A.W.C., Szeto, M.L., Lai, K.C., Hu, W.H.C., Chan, C.K., Xia, H.H.X., Yuen, M.F., Fung, F.M.Y., Tong, T.S.M., Ho, V.Y.K., Lam, S.K. & Wong, B.C.Y. One-week ranitidine bismuth citrate, amoxicillin and metronidazole triple therapy for the treatment of *Helicobacter pylori* infection in Chinese, 2067

Hungin, A.P.S. *see* Malfertheiner, P.

Hungin, A.P.S. *see* Rubin, G.

Hunt, R.H. *see* Huang, J.-Q.

Hunter, J.O. *see* Middleton, S.J.

Hurwitz, A. *see* Passaro, D.J.

hydroxypropylmethyl cellulose capsules, 1771

hypergastrinaemia, 1367

hyperplastic polyposis, 333

Iacopini, F. *see* Paoluzi, O.A.

Iannoni, C. *see* Paoluzi, O.A.

IBDQ, 1101

ICAM-1, 1761

leven, M.M. *see* De Block, C.E.M.

Iiritano, E. *see* Bilardi, C.

Iiritano, E. *see* Zentilini, P.

ileal pouch, 27

Imbesi, V. *see* Parente, F.

immunoassy, 1723
 immunosuppressants, 1751
 immunosuppression, 1939
 Inauen, W. *see* De Ponti, F.
 Inauen, W. *see* Netzer, P.
 induction, 381
 induction dosing, 2107
 infection, 1037
 inflammation, 1917, 2115
 inflammatory bowel disease, 197, 389, 647, 675, 919, 1125, 1503, 1579, 1743, 1895, 1997, 2053, 2061
 inflammatory disorders, 1509, 1831
 inflammatory polyposis, 333
 infliximab, 1101, 1117, 1579
 inguinal hernia, 1197
 integrated gastric acidity, 1819
 integrated oesophageal acidity, 1819
 interferon, 381, 1611
 interferon- α , 1091, 1633
 interferon- β , 1233
 interferon- γ -2b, 243
 interleukin-11, 399
 intestinal disorders, 1171, 1509
 intestinal epithelium, 1021
 intestinal metaplasia, 1449, 1923
 intestinal mucosa, 595
 intestinal permeability, 663
 intestinal protozoa, 595
 intestinal secretion, 769
 intragastric acidity, 899, 1301, 1317
 intragastric drug distribution, 217
 intragastric pH monitoring, 819
 intragastric pH, 425, 837, 1811
 intra-oesophageal pH, 435
 intra-uterine growth restriction, 1677
 irritable bowel syndrome, 343, 975, 985, 1187, 1395, 1407, 1649, 1701, 1877, 2081
 Isakov, V., Domareva, I., Koudryavtseva, L., Maev, I. & Ganskaya, Z. Furazolidone-based triple 'rescue therapy' vs. quadruple 'rescue therapy' for the eradication of *Helicobacter pylori* resistant to metronidazole, 1277
 Ishii, H. *see* Suzuki, M.
 Ishikawa, T. *see* Saitoh, T.
 Ishimura, N. *see* Hashimoto, T.
 Ishizaki, T. *see* Shirai, N.
 isosorbide mononitrate, 101
 Israeli, E. *see* Stockbrügger, R.W.
 Ito, M., Haruma, K., Kamada, T., Mihara, M., Kim, S., Kitadai, Y., Sumii, M., Tanaka, S., Yoshihara, M. & Chayama, K. *Helicobacter pylori* eradication therapy improves atrophic gastritis and intestinal metaplasia: a 5-year prospective study of patients with atrophic gastritis, 1449
 Jain, S.K. *see* Spechler, S.J.
 James, C.F. *see* Huang, J.-Q.
 Jansen, J.B.M.J. *see* Laheij, R.J.F.
 Jensen, R.T. *see* Bashir, S.
 Jewell, D.P. *see* Fraser, A.G.
 Jobson, B.A. *see* Shaw, I.S.
 Johansson, S. *see* Svedberg, P.
 Johnson, E. *see* Shaw, I.S.
 Johnson, L.B. *see* Marino, G.
 Johnsson, E. *see* Cange, L.
 Jokubaitis, L. *see* Robinson, M.
 Jones, A. *see* Malik, A.H.
 Jones, R. *see* Kamerling, I.M.C.
 Jones, R. *see* Malferttheiner, P.
 Joslyn, A. *see* Sytgat, G.N.J.
 Juliano, M.L. *see* Van Hecken, A.
 Jung, H.C. *see* Choi, I.J.
 Jung, H.C. *see* Kim, J.S.
 Kadyan, H. *see* Tankova, L.
 Kagawa, J. *see* Murakami, K.
 Kahl, S. *see* Peitz, U.
 Kajimura, M. *see* Shirai, N.
 Kamada, T. *see* Ito, M.
 Kamerling, I.M.C., Van Haarst, A.D., Burggraaf, J., Schoemaker, H.C., Biemond, I., Jones, R., Cohen, A.F. & Masleel, A.A.A. Dose-related effects of motilin on proximal gastrointestinal motility, 129
 Kamm, M.A. *see* Emmanuel, A.V.
 Kamm, M.A. *see* Hart, A.
 Kamm, M.A. *see* Hart, A.L.
 Kamm, M.A. *see* Mimura, T.
 Kamm, M.A. *see* Van Den Bogaerde, J.
 Kamm, M.A. Review article: the complexity of drug development for irritable bowel syndrome, 343
 Kanagawa, K. *see* Yoshikawa, I.
 Kane, S.V., Schoenfeld, P., Sandborn, W.J., Tremaine, W., Hofer, T. & Feagan, B.G. Systematic review: the effectiveness of budesonide therapy for Crohn's disease, 1509
 Kang, J.-Y., Tinto, A., Higham, J. & Majeed, A. Peptic ulceration in general practice in England and Wales 1994-98: period prevalence and drug management, 1067
 Kang, J.-Y. *see* Tinto, A.
 Kao, A.-W. *see* Sheu, B.-S.
 Karatapanis, S. *see* Georgopoulos, S.D.
 Karkavitsas, N. *see* Athanasakis, E.
 Katsube, T. *see* Hashimoto, T.
 Katsube, T. *see* Saitoh, T.
 Katz, J.A. *see* Tremaine, W.J.
 Katz, P.O. *see* Tutui, R.
 Kawamura, A. *see* Adachi, K.
 Keates, A.C. *see* Farrell, R.J.
 Keith, R.G. *see* Huang, J.-Q.
 Kelleher, D. *see* Mahmud, N.
 Kelly, C.P. *see* Farrell, R.J.
 Kelly, P. *see* Zulu, I.
 Kerr, G.D. *see* Green, J.R.B.
 Kerstens, R. *see* Sloots, C.E.J.

Khan, Z., MacDonald, C., Wicks, A.C., Holt, M.P., Floyd, D., Ghosh, S., Wright, N.A. & Playford, R.J. Use of the 'nutriceutical', bovine colostrum, for the treatment of distal colitis: results from an initial study. 1917

Kim, B.G. *see* Kim, J.S.

Kim, J.H. *see* Choi, I.J.

Kim, J.S., Kim, S.G., Choi, I.J., Park, M.J., Kim, B.G., Jung, H.C. & Song, I.S. Effect of *Helicobacter pylori* eradication on duodenal ulcer scar in patients with no clinical history of duodenal ulcer. 275

Kim, S. *see* Ito, M.

Kim, S.G. *see* Kim, J.S.

Kingstone, K. *see* Campbell, S.

Kinoshita, Y. *see* Adachi, K.

Kinoshita, Y. *see* Hashimoto, T.

Kinser, J.A. *see* Netzer, P.

Kitadai, Y. *see* Ito, M.

Kitahora, T. *see* Suzuki, M.

Klok, R.M., Brouwers, J.R.B.J., van den Berg, P.B., de Jong-van den Berg, L.T.W., Tolley, K. & Postma, M.J. Letter to the Editors. 1033

Kng, C. *see* Ng, F.H.

Knight, S.C. *see* Van Den Bogaerde, J.

Koay, E. *see* Lim, L.L.

Kobayashi, M. *see* Futagami, S.

Kodama, M. *see* Murakami, K.

Kogan, Z. *see* Sambuelli, A.

Kokkola, A., Sipponen, P., Rautelin, H., Härkönen, M., Kosunen, T.U., Haapiainen, R. & Puolakkainen, P. The effect of *Helicobacter pylori* eradication on the natural course of atrophic gastritis with dysplasia. 515

Koletzko, S. *see* Feydt-Schmidt, A.

Kong, H.L. *see* Lim, L.L.

Korn, S. *see* Tutuian, R.

Kosunen, T.U. *see* Kokkola, A.

Koudryavtseva, L. *see* Isakov, V.

Kovacs, T.O.G., Wilcox, C.M., Devault, K., Miska, D., Bochenek, W. & The Pantoprazole US Gerd Study Group B. Comparison of the efficacy of pantoprazole vs. nizatidine in the treatment of erosive oesophagitis: a randomized, active-controlled, double-blind study. 2043

Kowdley, K.V. *see* Whittington, C.A.

Kraus, M.R., Schäfer, A., Faller, H., Csef, H. & Scheurlen, M. Paroxetine for the treatment of interferon- α -induced depression in chronic hepatitis C. 1091

Krause, R. *see* Chen, C.L.

Krause, R. *see* Novick, J.

Kruidenier, L. & Verspaget, H.W. Review article: oxidative stress as a pathogenic factor in inflammatory bowel disease—radicals or ridiculous? 1997

Ksas, B. *see* Picard, C.

Kuiken, S.D., Lei, A., Tytgat, G.N.J., Holman, R. & Boeckxstaens, G.E.E. Effect of the low-affinity, noncompetitive N-methyl-D-aspartate receptor antagonist dextromethorphan on visceral perception in healthy volunteers. 1955

Kumar, D. *see* Zar, S.

Kumar, K.S. *see* Malik, A.H.

Kume, K. *see* Yoshikawa, I.

Kuo, B., Camilleri, M., Burton, D., Viramontes, B., McKinzie, S., Thomforde, G., O'Connor, M.K. & Brinkmann, B.H. Effects of 5-HT₃ antagonism on postprandial gastric volume and symptoms in humans. 225

Kuo, P.C. *see* Marino, G.

Kurosawa, A. *see* Hojo, M.

Kurotani, A. *see* Hashimoto, T.

Kurth, M.C. *see* Tremaine, W.J.

Labenz, J. *see* Peitz, U.

lactobacillus. 1461, 1669

lactose. 1591

Ladabaum, U., Chey, W.D., Scheiman, J.M. & Fendrick, A.M. Reappraisal of non-invasive management strategies for uninvestigated dyspepsia: a cost-minimization analysis. 1491

Ladas, S.D. *see* Georgopoulos, S.D.

Laheij, R.J.F., Van Rossum, L.G.M., De Boer, W.A. & Jansen, J.B.M.J. Corpus gastritis in patients with endoscopic diagnosis of reflux oesophagitis and Barrett's oesophagus. 887

Lahner, E., Bordi, C., Di Giulio, E., Caruana, P., D'Ambra, G., Milione, M., Grossi, C., Delle Fave, G. & Annibale, B. Role of *Helicobacter pylori* serology in atrophic body gastritis after eradication treatment. 507

Lahner, E. *see* Annibale, B.

Lai, C.H. *see* Poon, S.K.

Lai, C.-L. *see* Hui, C.-K.

Lai, C.L. *see* Ng, F.H.

Lai, K.C. *see* Hu, W.H.C.

Lai, K.-C. *see* Hui, C.-K.

Lai, K.C. *see* Hung, W.K.

Lai, K.C. *see* Ng, F.H.

Lai, K.C. *see* Wong, W.-M.

Lai, K.C. *see* Wong, W.M.

Lai, K.C. *see* Xia, H.H.-X.

Lai, M.Y. *see* Chang, C.H.

Lai, P.B.S. *see* Cheng, A.S.L.

Laine, L. & Dhir, V. *Helicobacter pylori* eradication does not worsen quality of life related to reflux symptoms: a prospective trial. 1143

Lam, C.L.K. *see* Hu, W.H.C.

Lam, K.F. *see* Hu, W.H.C.

Lam, S.K. *see* Hu, W.H.C.

Lam, S.-K. *see* Hui, C.-K.

Lam, S.K. *see* Hung, W.K.

Lam, S.K. *see* Ng, F.H.

Lam, S.K. *see* Wong, W.-M.

Lam, S.K. *see* Wong, W.M.

Lam, S.K. *see* Xia, H.H.-X.

Lamb, E.J., Wong, T., Smith, D.J., Simpson, D.E., Coakley, A.J., Moniz, C. & Muller, A.F. Metabolic bone disease is present at diagnosis in patients with inflammatory bowel disease. 1895

lamivudine and interferon treatments. 251

Lanas, A., Fuentes, J., Benito, R., Serrano, P., Bajador, E. & Sáinz, R. *Helicobacter pylori* increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin. 779

Lanas, A. *see* Serrano, P.

Landgraf, L. *see* Stockbrügger, R.W.
 Langaker, K.-E. *see* Tougas, G.
 Langman, M.J.S. *see* Hulin, S.J.
 Langmead, L., Dawson, C., Hawkins, C., Banna, N., Loo, S. & Rampton, D.S. Antioxidant effects of herbal therapies used by patients with inflammatory bowel disease: an *in vitro* study. 197
lansoprazole, 35, 291, 425, 553, 837, 881, 1149, 1811, 1933
 Lanza, F. *see* Chen, C.L.
laser Doppler, 1903
 Lau, C.P. *see* Wong, W.-M.
 Lau, S.F. *see* Yee, Y.K.
 Lau, W.H. *see* You, J.H.S.
 Lauritsen, K. *see* Hallerbäck, B.
 Lavagna, A. *see* Della Monica, P.
 Lavine, J.E. *see* Orenstein, S.R.
 Le Borgne, J. *see* Gournay, J.
 Le Néel, J.-C. *see* Gournay, J.
 Leandro, G. *see* Rugge, M.
 Lechago, J. *see* Rugge, M.
lectin, 633
 Ledermann, H. *see* Netzer, P.
 Lee, C.K. *see* Yee, Y.K.
 Lee, C.-L. *see* Liao, C.-C.
 Lee, K.K.C. *see* You, J.H.S.
 Lee, S.-C. *see* Liao, C.-C.
 Lee, S.-D. *see* Luo, J.-C.
 Lee, S.I. *see* Choi, I.J.
 Lee, W.M. *see* Malik, A.H.
 Lee, W.M. *see* Schiadt, F.V.
 Lee, Y.M. *see* Lim, L.L.
 Lee, Y.T. *see* Wu, J.C.Y.
 Leeds HELP Study Group *see* Mason, J.
 Lefkowitz, J. *see* Goldstein, J.L.
 Lefkowitz, M. *see* Novick, J.
 Lehmann, A. *see* Cange, L.
 Lehn, N. *see* Feydt-Schmidt, A.
 Lei, A. *see* Kuiken, S.D.
 Lemann, M. *see* Sabate, J.M.
 Lembcke, B. *see* Braden, B.
 Lengsfeld, H. *see* Faas, H.
 Leodolter, A. *see* Peitz, U.
 Leong, R.W.L. & Sung, J.J.Y. Review article: *Helicobacter* species and hepatobiliary diseases. 1037
 Leontiadis, G.I. *see* Levine, J.E.
 Lerat, F. *see* Gournay, J.
 Lerebours, E. *see* Abitbol, V.
 Leroux-Roels, G. *see* Van Vlierberghe, H.
 Leung, N.W.Y. *see* Cheng, A.S.L.
 Leung, W.K. *see* Wu, J.C.Y.
 Leung, W.K. & Sung, J.J.Y. Review article: intestinal metaplasia and gastric carcinogenesis. 1209
 Levine, J.E., Leontiadis, G.I., Sharma, V.K. & Howden, C.W. Meta-analysis: the efficacy of intravenous H₂-receptor antagonists in bleeding peptic ulcer. 1137
levosulpiride, 613
 Li, B.U.K. *see* Orenstein, S.R.
 Li, K.F. *see* Yee, Y.K.
 Liao, C.-C., Lee, C.-L., Chiang, T.-C., Lee, S.-C., Huang, S.-H., Tu, T.-C., Chen, T.-K. & Wu, C.-H. The ¹³C-urea breath test to detect *Helicobacter pylori* infection: a validated simple methodology with 50 mg ¹³C-urea. 787
 Liew, C.T. *see* Cheng, A.S.L.
 Ligozio, G. *see* Novick, J.
 Lim, L.L., Wai, C.T., Lee, Y.M., Kong, H.L., Lim, R., Koay, E. & Lim, S.G. Prophylactic lamivudine prevents hepatitis B reactivation in chemotherapy patients. 1939
 Lim, R. *see* Lim, L.L.
 Lim, S.G. *see* Lim, L.L.
 Lin, H.-Y. *see* Luo, J.-C.
 Lin, M.-D. *see* Sheu, B.-S.
 Lin, Y.-S. *see* Sheu, B.-S.
 Lind, T. *see* Malfertheiner, P.
 Lionetti, P. *see* Barabino, A.
 Lionello, M. *see* Manes, G.
lipid metabolism, 1571
lipids, 577
lipomatous polyposis, 333
liquid enema, 415
liver biopsy, 1963
liver cirrhosis, 1283, 1547
liver descriptors, 707, 1977
liver disease, 235, 1037
liver dysfunction, 1939
liver failure, 1539
liver transplantation, 1833, 1963
 Ljunghall, S. *see* Stockbrügger, R.W.
 Lloyd, D.A.J. *see* Tinto, A.
 Lo, C.-Y. *see* Sheu, B.-S.
 Loeffler, V. *see* Holtmann, G.
 Loftus Jr, E.V., Schoenfeld, P. & Sandborn, W.J. The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review. 51
 Logan, R.F.A. *see* Stack, W.A.
 Lombardo, L. *see* Della Monica, P.
London, 1709
 Lonovics, J. *see* Malfertheiner, P.
 Loo, S. *see* Langmead, L.
 Lopez, S. *see* Moreno-Monteguado, J.A.
 Lorenzo, J.A. *see* Moreno-Monteguado, J.A.
Los Angeles classification, 2037
 Losco, A. *see* Massironi, S.
 Lourens, S.T. *see* Netzer, P.
lower oesophageal sphincter, 473
loxiglumide, 17
 López-Sangomán, A. *see* Boixeda, D.
 Lüscher, D. *see* Netzer, P.
 Lu, C.-L. *see* Luo, J.-C.
 Lu, H. *see* Wong, W.M.
 Lu, R.-H. *see* Luo, J.-C.
 Lui, H.F. *see* Tripathi, D.
 Lumi, M. *see* Sambuelli, A.
 Lundell, L. *see* Cange, L.

Luo, J.-C., Chang, F.-Y., Lin, H.-Y., Lu, R.-H., Lu, C.-L., Chen, C.-Y. & Lee, S.-D. The potential risk factors leading to peptic ulcer formation in autoimmune disease patients receiving corticosteroid treatment. 1241

Lupascu, A. *see* Di Caro, S.

Luypaerts, A. *see* Geboes, K.P.

lymphocyte proliferation. 1903

lymphoma. 1225

Lymphoma Study Group, T.I.G. *see* Caletti, G.

Maastricht. 167, 1443

MacDonald, C. *see* Khan, Z.

Mack, R.J. *see* Chen, C.L.

Maconi, G. *see* Parente, F.

macrolide. 315, 1481

Madsen, L.G. & Bytzer, P. Review article: single subject trials as a research instrument in gastrointestinal pharmacology. 189

Maes, B. *see* Geboes, K.P.

Maev, I. *see* Isakov, V.

magnesium citrate. 1327

magnetic resonance imaging. 217

Mahmud, N., O'Toole, D., O'Hare, N., Freyne, P.J., Weir, D.G. & Kelleher, D. Evaluation of renal function following treatment with 5-aminosalicylic acid derivatives in patients with ulcerative colitis. 207

Majeed, A. *see* Kang, J.-Y.

Majeed, A. *see* Tinto, A.

Malchow, H., Gertz, B. & the Clafoam Study Group. A new mesalazine foam enema (Claversal Foam) compared with a standard liquid enema in patients with active distal ulcerative colitis. 415

Malek, M. *see* Musch, E.

Malet, P.F. *see* Malik, A.H.

Malfatti, F. *see* Giannini, E.

Mallertheiner, P., Dent, J., Zeijlon, L., Sipponen, P., Veldhuyzen van Zanten, S.J.O., Burman, C.-F., Lind, T., Wrangstadh, M., Bayerdörffer, E. & Lonovics, J. Impact of *Helicobacter pylori* eradication on heartburn in patients with gastric or duodenal ulcer disease — results from a randomized trial programme. 1431

Mallertheiner, P., Mégraud, F., O'Morain, C., Hungin, A.P.S., Jones, R., Axon, A., Graham, D.Y., Tytgat, G. & The European *Helicobacter pylori* Study Group (EHPSG). Current concepts in the management of *Helicobacter pylori* infection—The Maastricht 2-2000 Consensus Report. 167

Mallertheiner, P. *see* Ebert, M.P.A.

Mallertheiner, P. *see* Peitz, U.

Mallertheiner, P. *see* Pilotto, A.

malignancy. 1225, 1939

Malik, A.H., Kumar, K.S., Malet, P.F., Ostapowicz, G., Adams, G., Wood, M., Yarbrough, K., Jones, A. & Lee, W.M. A randomized trial of high-dose interferon alpha-2b, with or without ribavirin, in chronic hepatitis C patients who have not responded to standard dose interferon. 381

malondialdehyde. 985

MALT lymphoma. 1715

management strategies. 261, 1491

Mandelkern, M. *see* Mayer, E.A.

Manes, G., Balzano, A., Marone, P., Lioniello, M. & Mosca, S. Appropriateness and diagnostic yield of upper gastrointestinal endoscopy in an open-access endoscopy system: a prospective observational study based on the Maastricht guidelines. 105

Manfredi, R., Calza, L. & Chiodo, F. Gabexate mesilate and/or octreotide in human immunodeficiency virus-associated pancreatic abnormalities. 1791

Manfrin, V. *see* Fabris, P.

Manguso, F. *see* Rizzello, F.

Mansfield, J.C., Giaffer, M.H., Cann, P.A., McKenna, D., Thornton, P.C. & Holdsworth, C.D. A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis. 69

Mansfield, J.C. *see* Green, J.R.B.

Mansi, C. *see* Bilardi, C.

Mansi, C. *see* Zentilin, P.

Marcheggiano, A. *see* Paoluzi, O.A.

Marchiorotto, M.A.M. *see* Ortiz, R.A.M.

Marinaki, A. *see* Ansari, A.

Marino, G., Rustgi, V.K., Salzberg, G., Johnson, L.B., Kuo, P.C., Plotkin, J.S. & Flockhart, D.A. Pharmacokinetics and biochemical effects of hepatoprotein in patients with chronic liver disease. 235

Mar'kov chain. 41

Marone, P. *see* Manes, G.

Marteau, P., Cuillerier, E., Meance, S., Gerhardt, M.F., Myara, A., Bouvier, M., Bouley, C., Tondu, F., Bommelaer, G. & Grimaud, J.C. *Bifidobacterium animalis* strain DN-173 010 shortens the colonic transit time in healthy women: a double-blind, randomized, controlled study. 587

Martin, T. *see* Gournay, J.

Martin-De-Arigila, C. *see* Boixeda, D.

Mary, J.Y. *see* Abitbol, V.

Mas, P. *see* Calvet, X.

Masala, G. *see* Palli, D.

Mascole, A.A.A. *see* Kamerling, I.M.C.

Masliah, C. *see* Gournay, J.

Masoero, G. *see* Della Monica, P.

Mason, J., Axon, A.T.R., Forman, D., Duffett, S., Drummond, M., Crocombe, W., Feltbower, R., Mason, S., Brown, J. & Moayyedi, P. (on behalf of the Leeds HELP Study Group). The cost-effectiveness of population *Helicobacter pylori* screening and treatment: a Markov model using economic data from a randomized controlled trial. 559

Mason, S. *see* Mason, J.

Massironi, S., Losco, A., Basilisco, G., Wicks, A.C.B., Thomas, C., Curran, R. & Mayberry, J.F. Letters to the Editors. 1831

maternal infection. 1677

Maxwell, J.D. *see* Tinto, A.

Mayberry, J.F. *see* Massironi, S.

Mayer, E.A., Berman, S., Derbyshire, S.W.G., Suyenobu, B., Chang, L., Fitzgerald, L., Mandelkern, M., Hamm, L., Vogt, B. & Naliboff, B.D. The effect of the 5-HT₃ receptor antagonist, alosetron, on brain responses to visceral stimulation in irritable bowel syndrome patients. 1357

Mayr, P. *see* Holtmann, G.
 McCallum, R. *see* Pehlivanov, N.
 McGovern, D. *see* Fraser, A.G.
 McGuire, A.J. *see* Robinson, M.
 McGuire, J.A. *see* Orenstein, S.R.
 McIsaac, R.L. *see* Gardner, J.D.
 McKenna, D. *see* Mansfield, J.C.
 McKinzie, S. *see* Kuo, B.
 McPhail, G. *see* Zulu, I.
 Máday, E. *see* De Block, C.E.M.
MDR, 1021
 Meance, S. *see* Marteau, P.
 Mee, A.S. *see* Mitchell, S.A.
 Meenan, J. *see* Ansari, A.
 Mele, M.R. *see* Bilardi, C.
 Mele, M.R. *see* Zentilin, P.
 Menconi, M.J. *see* Farrell, R.J.
 Mendall, M.A. *see* Poullis, A.
 Menegatti, M. *see* Palli, D.
 Mentis, A. *see* Georgopoulos, S.D.
 Menzel, J. *see* Ullerich, H.
mercaptopurine, 181
 Merla, A. *see* Perri, F.
mesalazine, 647, 1889, 2053
mesenteric disorder, 2115
mesenteric panniculitis, 2115
meta-analysis, 1137, 1509, 1611, 1623
methotrexate, 647, 693, 1751
metronidazole, 27, 569, 793, 909, 1047, 1457, 2067
 Metz, M. *see* Holtmann, G.
 Meuwissen, S.G.M. *see* Sloots, C.E.J.
 Mégraud, F. *see* Malfertheiner, P.
microsomal hepatic function, 1977
 Middleton, S.J., Naylor, S., Woolner, J. & Hunter, J.O. A double-blind, randomized, placebo-controlled trial of essential fatty acid supplementation in the maintenance of remission of ulcerative colitis, 1131
 Midhagen, G. *see* Hallert, C.
 Miele, L. *see* Armuzzi, A.
 Miglioli, M. *see* Bortolotti, M.
 Miglioli, M. *see* Palli, D.
 Mihara, M. *see* Ito, M.
 Milicua, J.M. *see* Boixeda, D.
 Milione, M. *see* Lahner, E.
 Miller, N. *see* Warrington, S.
 Mills, P.R. *see* Stockbrügger, R.W.
 Mimura, T., Rizzello, F., Helwig, U., Poggioli, G., Schreiber, S., Talbot, I.C., Nicholls, R.J., Gionchetti, P., Campieri, M. & Kamm, M.A. Four-week open-label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis, 909
 Miner Jr, P.B. *see* Collings, K.L.
 Miner Jr, P.B. *see* Gardner, J.D.
 Miner, P. *see* Novick, J.
 Miner, P.B. *see* Robinson, M.
 Miska, D. *see* Kovacs, T.O.G.
 Mitchell, S.A., Mee, A.S., Smith, G.D., Palmer, K.R. & Chapman, R.W. Alverine citrate fails to relieve the symptoms of irritable bowel syndrome: results of a double-blind, randomized, placebo-controlled trial, 1187
mitochondrial liver function, 1977
 Mitry, E. *see* Faivre-Finn, C.
 Miwa, H. *see* Hojo, M.
mixed infection, 2073
 Miyake, K. *see* Futagami, S.
 Miyazawa, M. *see* Suzuki, M.
 Moayyedi, P. *see* Mason, J.
 Modigliani, R. *see* Sabate, J.M.
 Mohnen, J. *see* Hirschowitz, B.I.
 Moniz, C. *see* Lamb, E.J.
 Montgomery, S.M. *see* Wakefield, A.J.
 Montigny, P. *see* Gournay, J.
 Mordenti, J. *see* Tremaine, W.J.
 Morelli, A. *see* Distrutti, E.
 Morelli, P. *see* Bazzoli, F.
 Moreno, V. *see* Elizalde, J.I.
 Moreno-Montagudo, J.A., Castro, A., De Pedro, A., Lorenzo, J.A., Fernández-Bermejo, M., Lopez, S., García-Buey, L., Borque, M.J., Pedreira, J.D. & Moreno-Otero, R. Interferon- α plus ribavirin for 12 months increases the sustained response rates in chronic hepatitis C relapsers, 243
 Moreno-Otero, R. *see* Moreno-Montagudo, J.A.
 Mori, H. *see* Saitoh, T.
 Morillas, J.D. *see* Elizalde, J.I.
 Morocutti, A. *see* Warrington, S.
 Morsiani, E. *see* Pazzi, P.
mortality, 2037
 Morton, D. *see* Fraser, A.G.
mosapride, 959
 Mosca, S. *see* Manes, G.
motilide, 1481
motilin, 129
motility, 603, 743
motility and nerve-gut interactions, 1171, 1571, 1781, 1955
oxifloxacin, 527
mucosal injury, 847
 Muhtarov, M. *see* Tankova, L.
 Mullan, B.P. *see* Cremonini, F.
 Muller, A.F. *see* Lamb, E.J.
 Muraca, M. *see* Pazzi, P.
 Murakami, K., Sato, R., Okimoto, T., Nasu, M., Fujioka, T., Kodama, M., Kagawa, J., Sato, S., Abe, H. & Arita, T. Eradication rates of clarithromycin-resistant *Helicobacter pylori* using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin, 1933
 Murata, I. *see* Yoshikawa, I.
 Murch, S.H. *see* Wakefield, A.J.
 Murray, H. *see* Eslick, G.D.
 Murray, J.A. *see* Nzeako, U.C.
 Murthy, A. *see* Robinson, M.
 Musch, E., Andus, T. & Malek, M. Induction and maintenance of clinical remission by interferon- β in patients with steroid-

refractory active ulcerative colitis—an open long-term pilot trial. 1233

Musulen, E. *see* Calvet, X.

Myara, A. *see* Marteau, P.

Nagahashi, S. *see* Suzuki, M.

Nakamura, H. *see* Yoshikawa, I.

Naliboff, B.D. *see* Mayer, E.A.

naloxone, 1649

Nasu, M. *see* Murakami, K.

natalizumab, 699

Nault, B. *see* Tougas, G.

nausea, 225

Naylor, S. *see* Middleton, S.J.

Negreira, S. *see* Sambuelli, A.

Netzer, P., Gaia, C., Lourens, S.T., Reber, P., Wildi, S., Noelpp, U., Ritter, E.P., Ledermann, H., Lüscher, D., Varga, L., Kinser, J.A., Büchler, M.W. & Scheurer, U. Does intravenous ondansetron affect gastric emptying of a solid meal, gastric electrical activity or blood hormone levels in healthy volunteers? 119

Netzer, P., Schmitt, B. & Inauen, W. Effects of ABT-229, a motilin agonist, on acid reflux, oesophageal motility and gastric emptying in patients with gastro-oesophageal reflux disease, 1481

Netzer, R., DeGiorgio, M.C., Bateson, H.K., Parsons, P. *see* De Ponti, F.

neurodevelopment, 663

neuroleptics, 1539

neutrophil, 159

Nevens, F. *see* Van De Castele, M.

New York, 1709

Newton, J.M. *see* Tuleu, C.

Ng, F.H., Wong, W.M., Wong, B.C.Y., Kng, C., Wong, S.Y., Lai, K.C., Cheng, C.S., Yuen, W.C., Lam, S.K. & Lai, C.L. Sequential intravenous/oral antibiotic vs. continuous intravenous antibiotic in the treatment of pyogenic liver abscess, 1083

Nicholls, R.J. *see* Mimura, T.

Nicholls, T.J. *see* Emmanuel, A.V.

Nicolini, G. *see* Bazzoli, F.

Ni'Muircheartaigh, R. *see* Sengupta, S.

Nista, E.C. *see* Armuzzi, A.

Nista, E.C. *see* Cremonini, F.

Nista, E.C. *see* Di Caro, S.

nitrates, 1945

nitroimidazole, 315

nizatidine, 297, 2043

nociceptive fibres, 1075

nocturnal acid breakthrough, 1309

Noelpp, U. *see* Netzer, P.

N-of-1 trials, 189

non-cardiac chest pain, 465, 1217

non-responders, 1611

non-response, 1743

non-steroidal anti-inflammatory drugs, 497, 1241, 1945

non-surgical, 1

non-transferrin-bound iron, 1555

non-ulcer dyspepsia, 1689

normal values, 1781

North America, 51

Northfield, T.C. *see* Poullis, A.

Nouel, J.F. *see* Gournay, J.

Novick, J., Miner, P., Krause, R., Glebas, K., Bliesath, H., Ligozio, G., Rüegg, P. & Lefkowitz, M. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation, 1877

NSAID, 847

nuclear factor κ B (NF κ B), 1579

nucleoside analogue, 1939

nutrition, 799

Nygard, G. *see* Stockbrügger, R.W.

Nzeako, U.C. & Murray, J.A. An evaluation of the clinical implications of acid breakthrough in patients on proton pump inhibitor therapy, 1309

observational study, 1663

obstructive jaundice, 727

O'Connor, H.J. *Helicobacter pylori* and dyspepsia: physicians' attitudes, clinical practice, and prescribing habits, 487

O'Connor, M.K. *see* Kuo, B.

octreotide, 769, 1563, 1791

O'Donnell, L.J.D. *see* Sengupta, S.

oesophageal, 799

oesophageal disorder, 1209, 1955

oesophageal manometry, 893

oesophageal motility, 1481

oesophageal pH monitoring, 545

oesophageal pH, 1655

oesophageal stricture, 1795

oesophageal ulcer, 1795

oesophagitis, 2037

oesophagus, 2029

Ofman, J.J., Dorn, G.H., Fennerty, M.B. & Fass, R. The clinical and economic impact of competing management strategies for gastro-oesophageal reflux disease, 261

Ogawa, K. *see* Saitoh, T.

O'Hare, N. *see* Mahmud, N.

Ohashi, K. *see* Shirai, N.

Ohkawa, S. *see* Saitoh, T.

Ohkura, R. *see* Hojo, M.

Ohkusa, T. *see* Hojo, M.

Ojeaburu, J.V. *see* Bashir, S.

Ojetti, V. *see* Di Caro, S.

Okimoto, T. *see* Murakami, K.

Olden, K. *see* El-Serag, H.B.

Oldenburg, B. *see* van Balkom, B.P.J.

O'Leary, J.J. *see* Wakefield, A.J.

Olyaei, M. *see* Pehlivanov, N.

omeprazole, 35, 137, 145, 479, 553, 569, 1149, 1163, 1431, 1811

O'Morain, C. *see* Malfertheiner, P.

oncology, 1059

ondansetron, 119

Ono, M. *see* Adachi, K.

opioid analgesics, 1539

Opolon, P. *see* Goulenok, C.
oral contraceptives, 1539

Orchard, T.R. *see* Fraser, A.G.

Orenstein, S.R., Blumer, J.L., Faessel, H.M., McGuire, J.A., Fung, K., Li, B.U.K., Lavine, J.E., Grunow, J.E., Treem, W.R. & Ciocia, A.A. Ranitidine, 75 mg, over-the-counter dose: pharmacokinetic and pharmacodynamic effects in children with symptoms of gastro-oesophageal reflux, 899

Orr, W.C. *see* Chen, C.L.

Ortiz, R.A.M., Calafatti, S.A., Corazzi, A., Souza, J.M., Deguer, M., De Souza, C.A.F., Marchioretto, M.A.M., Bernasconi, G., Ferraz, J.G.P. & Pedrazzoli Jr, J. Amoxicillin and ampicillin are not transferred to gastric juice irrespective of *Helicobacter pylori* status or acid blockade by omeprazole, 1163

Ostapowicz, G. *see* Malik, A.H.

osteoporosis, 919, 1519, 1895

O'Toole, D. *see* Mahmud, N.

Otsuka, H. *see* Saitoh, T.

Otsuki, M. *see* Yoshikawa, I.

Ott, P. *see* Schioldt, F.V.

Otten, M.H. *see* Tougas, G.

outcomes research, 1003

oxidative stress, 1997

pain, 225, 1075

Paineau, J. *see* Gournay, J.

Pajares, J.M. *see* Gisbert, J.P.

Palli, D., Menegatti, M., Masala, G., Ricci, C., Saieva, C., Holton, J., Gatta, L., Miglioli, M. & Vaira, D. *Helicobacter pylori* infection, anti-cagA antibodies and peptic ulcer: a case-control study in Italy, 1015

palliative chemotherapy, 353

Palmer, K.R. *see* Mitchell, S.A.

Palmer, T. *see* Gordon, F.H.

pancreatic abnormalities, 1791

pancreatic disorders, 1831, 2097

Pandofo, N. *see* Zentilin, P.

pantoprazole, 425, 553, 1457, 2043

Paoluzi, O.A., Pica, R., Marcheggiano, A., Crispino, P., Iacopini, F., Iammoni, C., Rivera, M. & Paoluzi, P. Azathioprine or methotrexate in the treatment of patients with steroid-dependent or steroid-resistant ulcerative colitis: results of an open-label study on efficacy and tolerability in inducing and maintaining remission, 1751

Paoluzi, P. *see* Paoluzi, O.A.

paracetamol, 1539

Parente, F., Bargiggia, S. & Bianchi Porro, G. Prospective audit of gastroscopy under the 'three-day rule': a regional initiative in Italy to reduce waiting time for suspected malignancy, 1011

Parente, F., Sainaghi, M., Sangaletti, O., Imbesi, V., Maconi, G., Anderloni, A. & Bianchi Porro, G. Different effects of short-term omeprazole, lansoprazole or pantoprazole on the accuracy of the ^{13}C -urea breath test, 553

Parente, F. *see* Caletti, G.

parietal cell antibodies, 281

Park, M.J. *see* Kim, J.S.

Parker, R.A. *see* Spechler, S.J.

paroxetine, 1091

Parsonnet, J. *see* Passaro, D.J.

Passaro, D.J., Hurwitz, A., Triadafilopoulos, G. & Parsonnet, J. A modification of the quininium resin test for assessing gastric acidity, 875

pathogenesis, 1037

pathogenicity island, 1015

pathophysiology, 1407

patients, 1877

patients compliance, 527, 1889, 2053

Pazzi, P., Morsiani, E., Vilei, M.T., Granato, A., Rozga, J., Demetriou, A.A. & Muraca, M. Serum bile acids in patients with liver failure supported with a bioartificial liver, 1547

PCA, 799

Peña, B.M. *see* Goldstein, J.L.

Pecher, E. *see* Tougas, G.

Pedersen, N.L. *see* Svedberg, P.

pediatric, 899

Pedrazzoli Jr, J. *see* Ortiz, R.A.M.

Pedreira, J.D. *see* Moreno-Monteagudo, J.A.

Pehlivanov, N., Sarosiek, I., Whitman, R., Olyaei, M. & McCallum, R. Effect of cisapride on nocturnal transient lower oesophageal sphincter relaxations and nocturnal gastro-oesophageal reflux in patients with oesophagitis: a double-blind, placebo-controlled study, 743

Peitz, U., Sulliga, M., Wolle, K., Leodolter, A., Von Arnim, U., Kahl, S., Stolte, M., Börsch, G., Labenz, J. & Malfertheiner, P. High rate of post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure *Helicobacter pylori* infection: impact of two second-line therapies in a randomized study, 315

Pelckmans, P.A. *see* De Block, C.E.M.

Pensi, M.O. *see* Distrutti, E.

pepsin, 303

pepsinogen A/C ratio, 1805

pepsinogen I, 1723

peptic disease, 1469

peptic ulcer bleeding, 137

peptic ulcer disease, 1241

peptic ulcer, 497, 1015, 1067, 1163, 1203, 1945

percutaneous ethanol injection, 1529

Pera, A. *see* Della Monica, P.

Perdomo, C. *see* Gardner, J.D.

Perego, A. *see* Sambuelli, A.

Perri, F., Ricciardi, R., Merla, A., Piepoli, A., Gasperi, V., Quitadamo, M. & Andriulli, A. Appropriateness of urea breath test: a prospective observational study based on Maastricht 2000 guidelines, 1443

Persson, T. *see* Stockbrügger, R.W.

Petty, K.J. *see* Van Hecken, A.

Peyre, S. *see* Caletti, G.

PGA, 799

PGC, 799

P-glycoprotein, 1021

pH, 303

pharmaceutical industry, 1859

pharmacodynamics, 899

pharmacoeconomy, 1269
 pharmacokinetics, 235, 899, 1163
 phasic motility, 985
 pH-metry, 893
 pH-monitoring, 869
 phytohaemagglutinin, 633
 Pica, R. *see* Paoluzi, O.A.
 Picard, C., Ksas, B., Griffiths, N.M. & Fioramonti, J. Effect of granisetron on radiation-induced alterations of colonic motility and fluid absorption in rats, 623
 Piccinino, F. *see* Gaeta, G.B.
 Piepoli, A. *see* Perri, F.
 Pileri, S. *see* Caletti, G.
 Pilmer, B.L. *see* Huang, J.-Q.
 Pilotto, A. *see* Fabris, P.
 Pilotto, A. & Malferttheiner, P. Review article: an approach to *Helicobacter pylori* infection in the elderly, 683
 Piqué, J.M. *see* Elizalde, J.I.
 placebo-controlled study, 959
 platelets, 577
 Playford, R.J. *see* Khan, Z.
 Plotkin, J.S. *see* Marino, G.
 Pochapin, M.B. *see* Rex, D.K.
 Poen, A.C. *see* Sloots, C.E.J.
 Poggioli, G. *see* Mimura, T.
 poisoning, 1539
 Polegato, S. *see* Giannini, E.
 polyethylene glycol, 1327
 polyps, 1197
 Poon, S.K., Chang, C.S., Su, J., Lai, C.H., Yang, C.C., Chen, G.H. & Wang, W.-C. Primary resistance to antibiotics and its clinical impact on the efficacy of *Helicobacter pylori* lansoprazole-based triple therapies, 291
 population screening, 559
 population survey, 2081
 Poremba, C. *see* Ullerich, H.
 portal hypertension, 373
 Porter, J. *see* Högenauer, C.
 Postma, M.J. *see* Klok, R.M.
 post-sphincterotomy bleeding, 929
 pouchitis, 27, 909
 Poullis, A., Foster, R., Northfield, T.C. & Mendall, M.A. Review article: faecal markers in the assessment of activity in inflammatory bowel disease, 675
 Pounder, R.E. *see* Gordon, F.H.
 Poynard, T. *see* Goulenok, C.
 Pozzato, P. *see* Bazzoli, F.
 Prada, A. *see* Rizzello, F.
 Praet, M. *see* Van Vlierberghe, H.
 prebiotic, 1591
 Precone, D.F. *see* Gaeta, G.B.
 Price, A.B. *see* Rugge, M.
 Prinz, C. *see* Voland, P.
 Probert, C.S.J. *see* Shaw, I.S.
 probiotics, 587, 1461
 proctocolectomy, 27
 prokinetic, 1347
 prokinetic drugs, 749
 prolonged manometry study, 985
 propanolol, 373
 Proskin, H.M. *see* Collings, K.L.
 prospective follow-up study, 2037
 proton pump inhibitor, 159, 473, 819, 1047, 1301, 1149
 prucalopride, 603, 759
 Pruitt, R.E. *see* Tougas, G.
 Puig, J. *see* Calvet, X.
 Puleston, J.M. *see* Wakefield, A.J.
 Puolakkainen, P. *see* Kokkola, A.
 pyogenic liver abscess, 1083
 quadruple therapy, 569, 1261, 1457
 quality of life, 909, 1101, 1143, 1347, 1603
 Que, T.L. *see* Yee, Y.K.
 questionnaire, 1101
 quinine, 875
 quininium resin, 875
 Quitadamo, M. *see* Perri, F.
 Qureshi, W. *see* Verghese, V.J.
 rabeprazole, 445, 455, 479, 1149, 1301, 1811, 1933
 Rades, T. *see* Faas, H.
 Rakatansky, H. Review article: gastroenterology and the pharmaceutical industry, 1859
 Rampton, D.S. *see* Langmead, L.
 randomized controlled trial, 479, 559
 randomized trial, 569
 ranitidine, 899, 1317
 ranitidine bismuth citrate, 2067
 Rank, M.R. *see* Cremonini, F.
 rapid urine test, 813
 Raptis, S.A. *see* Georgopoulos, S.D.
 Rassiat, E. *see* Faivre-Finn, C.
 rat, 623
 Rautelin, H. *see* Kokkola, A.
 Rea, P. *see* Franzese, A.
 reactive oxygen metabolites, 197, 1997
 Reber, P. *see* Neizer, P.
 reflux, 35, 881
 reflux disease, 41
 reflux oesophagitis, 545, 887, 1431
 Rüegg, P. *see* Novick, J.
 relapsers, 243
 renal and urinary tract problems, 975
 renal function, 207
 repair, 1917
 reproducibility, 1781
 rescue, 1047
 resistance, 315
 resistance to metronidazole, 1277
 responder, 1805
 restorative, 27
 retreatment, 1047
 Rew, J.S. *see* Choi, I.J.

Rex, D.K., Chasen, R. & Pochapin, M.B. Safety and efficacy of two reduced dosing regimens of sodium phosphate tablets for preparation prior to colonoscopy. 937

Rhee, J.C. *see* Choi, J.

rheumatoid arthritis. 1291

Rhodes, J. *see* Hawkes, N.D.

Rhodes, P. *see* Hawkes, N.D.

ribavirin. 234, 381, 1611, 1623, 1633, 2107

Ricci, C. *see* Palli, D.

Ricciardi, R. *see* Perri, F.

Ricciardiello, L. *see* Bazzoli, F.

Richou, C. *see* Gournay, J.

ridogrel. 87

Riff, D. *see* Chen, C.L.

risk factors. 1519, 1623

Ritter, E.P. *see* Netzer, P.

Rivera, M. *see* Paoluzi, O.A.

Rizzello, F., Gionchetti, P., D'Arienzo, A., Manguso, F., Di Matteo, G., Annese, V., Valpiani, D., Casetti, T., Adamo, S., Prada, A., Castiglione, G.N., Varoli, G. & Campieri, M. Oral beclometasone dipropionate in the treatment of active ulcerative colitis: a double-blind placebo-controlled study. 1109

Rizzello, F. *see* Mimura, T.

Robinson, E.M. *see* Fraser, A.G.

Robinson, M., Fitzgerald, S., Hegedus, R., Murthy, A. & Jokubaitis, L. (on behalf of the FAST trial investigators). Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis. 445

Robinson, M., Rodriguez-Stanley, S., Miner, P.B., McGuire, A.J., Fung, K. & Ciociola, A.A. Effects of antacid formulation on postprandial oesophageal acidity in patients with a history of episodic heartburn. 435

Robinson, M. *see* Collings, K.L.

Robinson, M. *see* Gardner, J.D.

Roda, E. *see* Bazzoli, F.

Rodriguez-Stanley, S. *see* Collings, K.L.

Rodriguez-Stanley, S. *see* Gardner, J.D.

Rodriguez-Stanley, S. *see* Robinson, M.

Rojavin, M.A. *see* Tougas, G.

Romagnoli, P. *see* Giannini, E.

Ros, E. *see* Elizalde, J.I.

Rosinach, M. *see* Domènech, E.

Rothenbacher, D., Bode, G. & Brenner, H. Dynamics of *Helicobacter pylori* infection in early childhood in a high-risk group living in Germany: loss of infection higher than acquisition. 1663

Roux, C. *see* Abitbol, V.

Rowley-Jones, D. *see* Gordon, F.H.

Roy, A.J. *see* Emmanuel, A.V.

Rozga, J. *see* Pazzi, P.

Rüssmann, H. *see* Feydt-Schmidt, A.

Rubin, G., Hungin, A.P.S., Chinn, D., Dwarakanath, A.D., Green, L. & Bates, J. Long-term aminosalicylate therapy is under-used in patients with ulcerative colitis: a cross-sectional survey. 1889

Rugge, M., Correa, P., Dixon, M.F., Fiocca, R., Hattori, T., Lechago, J., Leandro, G., Price, A.B., Sipponen, P., Solcia, E., Watanabe, H. & Genta, R.M. Gastric mucosal atrophy: interobserver consistency using new criteria for classification and grading. 1249

Russel, M.G.V.M. *see* van Balkom, B.P.J.

Rustgi, V.K. *see* Marino, G.

Rutgeerts, P. *see* Geboes, K.P.

Ruth, M. *see* Cange, L.

Rydholm, H. *see* Cange, L.

Rydholm, H. *see* Van Herwaarden, M.A.

Rydén-Bergsten, T. *see* Vakil, N.

Sabate, J.M., Villarejo, J., Lemann, M., Bonnet, J., Allez, M. & Modigliani, R. An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease. 1117

Saccharomyces boulardii. 1461

Sachs, G. *see* Voland, P.

Safdi, M. *see* Sands, B.E.

safety. 1623, 1701

Saieva, C. *see* Palli, D.

Sainaghi, M. *see* Parente, F.

Saitoh, T., Fukushima, Y., Otsuka, H., Hirakawa, J., Mori, H., Asano, T., Ishikawa, T., Katsume, T., Ogawa, K. & Ohkawa, S. Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers. 1811

Sakamoto, C. *see* Futagami, S.

salivary secretion. 297

salvage. 1047

Salzberg, B. *see* Sands, B.E.

Salzberg, G. *see* Marino, G.

Sambuelli, A., Boerr, I., Negreira, S., Gil, A., Camartino, G., Huernos, S., Kogan, Z., Cabanne, A., Graziano, A., Peredo, A., Doldán, I., Gonzalez, O., Sugai, E., Lumi, M. & Bai, J.C. Budesonide enema in pouchitis—a double-blind, double-dummy, controlled trial. 27

Sampliner, R.E. *see* Sonnenberg, A.

Samsom, M. *see* Clemens, C.H.M.

Samsom, M. *see* De Schryver, A.M.P.

Samsom, M. *see* Van Herwaarden, M.A.

San Miguel, R., Guillén, F., Cabasés, J.M. & Buti, M. Meta-analysis: combination therapy with interferon- α 2a/2b and ribavirin for patients with chronic hepatitis C previously non-responsive to interferon. 1611

Sandborn, W.J. *see* Kane, S.V.

Sandborn, W.J. *see* Loftus Jr, E.V.

Sanderson, J. *see* Ansari, A.

Sands, B.E., Winston, B.D., Salzberg, B., Safdi, M., Barish, C., Wruble, L., Wilkins, R., Shapiro, M., Schwertschlag, U.S. & the rhl-11 Crohn's Study Group. Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease. 399

Sanfeliu, I. *see* Calvet, X.

Sangaletti, O. *see* Parente, F.

Santa Ana, C. *see* Högenauer, C.

Sarosiek, I. *see* Pehlivanov, N.

Sasaki, M., Fitzgerald, A.J., Grant, G., Ghatei, M.A., Wright, N.A. & Goodlad, R.A. Lectins can reverse the distal intestinal atrophy associated with elemental diets in mice. 633

Sato, N. *see* Hojo, M.

Sato, R. *see* Murakami, K.

Sato, S. *see* Murakami, K.

Savarino, V. *see* Bilardi, C.

Savarino, V. *see* Frazzoni, M.

Savarino, V. *see* Zentilin, P.

Schaub, M. *see* Braden, B.

Scheiman, J.M. *see* Ladabaum, U.

Scheurer, U. *see* Netzer, P.

Scheurlen, M. *see* Kraus, M.R.

Schäfer, A. *see* Kraus, M.R.

Schioldt, F.V., Lee, W.M., Bondesen, S., Ott, P. & Christensen, E. Influence of acute and chronic alcohol intake on the clinical course and outcome in acetaminophen overdose. 707

Schmidt, L.E. & Dalhoff, K. The effect of regular medication on the outcome of paracetamol poisoning. 1539

Schmitt, B. *see* Netzer, P.

Schnée, M. *see* Gournay, J.

Schnell, T.G. *see* Avidan, B.

Schoemaker, H.C. *see* Kamerling, I.M.C.

Schoenfeld, P. *see* Kane, S.V.

Schoenfeld, P. *see* Loftus Jr, E.V.

Schoon, E.J. *see* Stockbrügger, R.W.

Schoon, E.J. *see* van Balkom, B.P.J.

Schreiber, S. *see* Mimura, T.

Schwartz, S. *see* Chen, C.L.

Schwartschlag, U.S. *see* Sands, B.E.

Schwizer, W. *see* Faas, H.

Scott, B.B. *see* Cunliffe, R.N. screening for colorectal cancer. 1197

second-line. 793, 1047

second-line therapy. 569

second-line treatment. 315

Seed, P. *see* Ansari, A.

selective serotonin₄receptor agonist. 759

Sengupta, S., Cooney, R., Baj, M., Ni'Muircheartaigh, R. & O'Donnell, L.J.D. Prokinetic effect of indoramin, an α -adrenergic antagonist, on human gall-bladder. 1801

sensitivity. 735

sequential therapy. 1083

Seriolo, B. *see* Zentilin, P.

serological tests. 521

serology. 507, 533, 1015

serotonin. 1357, 1367

serotonin receptors. 1563

Serrano, P., Lanas, A., Arroyo, M.T. & Ferreira, I.J. Risk of upper gastrointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular diseases. 1945

Serrano, P. *see* Lanas, A.

serum gastrin. 1301

Servaes, R. *see* Van De Castele, M.

Sewell, K.L. *see* Yacyshyn, B.R.

Sham, F.N.F. *see* Xia, H.H.-X.

Shapiro, M. *see* Sands, B.E.

Sharma, V.K. *see* Levine, J.E.

Shaw, I.S., Jobson, B.A., Silverman, D., Ford, J., Hearing, S.D., Ball, D., Johnson, E., Day, A. & Probert, C.S.J. Is your patient taking the medicine? A simple assay to measure compliance with 5-aminosalicylic acid-containing compounds. 2053

Sheu, B.-S., Chi, C.-H., Huang, C.-C., Kao, A.-W., Wang, Y.-L. & Yang, H.-B. Impact of intravenous omeprazole on *Helicobacter pylori* eradication by triple therapy in patients with peptic ulcer bleeding. 137

Sheu, B.-S., Wu, J.-J., Lo, C.-Y., Wu, H.-W., Chen, J.-H., Lin, Y.-S. & Lin, M.-D. Impact of supplement with *Lactobacillus*- and *Bifidobacterium*-containing yogurt on triple therapy for *Helicobacter pylori* eradication. 1669

Shirai, N., Furuta, T., Xiao, F., Kajimura, M., Hanai, H., Ohashi, K. & Ishizaki, T. Comparison of lansoprazole and famotidine for gastric acid inhibition during the daytime and night-time in different CYP2C19 genotype groups. 837

Shirai, N. *see* Furuta, T.

Shobowale-Bakre, E.-M. *see* Ansari, A.

short- and long-segment. 893

Sianongo, S. *see* Zulu, I.

side effects. 647, 1125, 1503, 1831

Sik Chung, I. *see* Choi, I.J.

Silverman, D. *see* Shaw, I.S.

simethicone. 1641

Simmons, J. *see* Hirschowitz, B.I.

Simpson, D.E. *see* Lamb, E.J.

Singh, S. *see* Hulin, S.J.

single-subject trials. 189

Sainz, R. *see* Lanas, A.

Sipponen, P. *see* Kokkola, A.

Sipponen, P. *see* Malferttheiner, P.

Sipponen, P. *see* Rugge, M.

Sloan, S. *see* Gardner, J.D.

Sloots, C.E.J., Poen, A.C., Kerstens, R., Stevens, M., De Pauw, M., Van Oene, J.C., Meuwissen, S.G.M. & Felt-Bersma, R.J.F. Effects of prucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipation. 759

small intestine. 769

Smith, D.J. *see* Lamb, E.J.

Smith, G.D. *see* Mitchell, S.A.

smoking. 497

Smout, A.J.P.M. *see* Clemens, C.H.M.

Smout, A.J.P.M. *see* De Schryver, A.M.P.

Smout, A.J.P.M. *see* Van Herwaarden, M.A.

Snape Jr, W.J. *see* Tougas, G.

sodium phosphate. 937

Soergel, K.H. *see* Huilgol, V.

Soffiati, G. *see* Fabris, P.

Solcia, E. *see* Rugge, M.

Soloway, R.D. *see* Chen, C.L.

Song, I.S. *see* Kim, J.S.

Soni, A. *see* Sonnenberg, A.

Sonnenberg, A., Soni, A. & Sampliner, R.E. Medical decision analysis of endoscopic surveillance of Barrett's oesophagus to prevent oesophageal adenocarcinoma. 41

Sonnenberg, A. *see* Avidan, B.

Sonnenberg, A. *see* Baron, J.H.
 Sonnenberg, A. & Gavin, M.W. General principles to enhance practice patterns in gastrointestinal endoscopy, 1003
 Sontag, S.J. *see* Avidan, B.
 Soule, J.C. *see* Abitbol, V.
 Souza, J.M. *see* Ortiz, R.A.M.
 Spadaro, A. *see* Gaeta, G.B.
 Spechler, S.J., Jain, S.K., Tendler, D.A. & Parker, R.A. Racial differences in the frequency of symptoms and complications of gastro-oesophageal reflux disease, 1795
species, 1037
specificity, 735
 Spiliadi, C. *see* Georgopoulos, S.D.
 Spurrett, B. *see* Eslick, G.D.
 Sridhar, S. *see* Huang, J.-Q.
SSRI, 1091
 Stack, W.A., Atherton, J.C., Hawkey, G.M., Logan, R.F.A. & Hawkey, C.J. Interactions between *Helicobacter pylori* and other risk factors for peptic ulcer bleeding, 497
stage at diagnosis, 353
 Stagg, A.J. *see* Hart, A.L.
 Stanley, A.J. *see* Tripathi, D.
 Stanzione, M. *see* Gaeta, G.B.
 Steinboecker, A. *see* Faas, H.
stenosis, 1203
steroid-refractoriness, 2061
 Stevens, M. *see* Sloots, C.E.J.
 Stockbrügger, R.W., Schoon, E.J., Bollani, S., Mills, P.R., Israeli, E., Landgraf, L., Felsenberg, D., Ljunghall, S., Nygard, G., Persson, T., Graffner, H., Bianchi Porro, G. & Ferguson, A. Discordance between the degree of osteopenia and the prevalence of spontaneous vertebral fractures in Crohn's disease, 1519
 Stockbrügger, R.W. *see* van Balkom, B.P.J.
stol, 1723
stol test, 1663
 Stolte, M. *see* Peitz, U.
stomach, 225, 1075
stool antigen assay, 1733
 Stornaiuolo, G. *see* Gaeta, G.B.
 Strenkoski-Nix, L.C. *see* Tremaine, W.J.
stress, 2017
 Störk, D. *see* Feydt-Schmidt, A.
 Ström, M. *see* Hallert, C.
 Su, J. *see* Poon, S.K.
 Sugai, E. *see* Sambuelli, A.
sulfasalazine, 61, 69, 647
 Sulliga, M. *see* Peitz, U.
sulphide, 325
 Sumii, M. *see* Ito, M.
 Sung, J.J.Y. *see* Cheng, A.S.L.
 Sung, J.J.Y. *see* Leong, R.W.L.
 Sung, J.J.Y. *see* Leung, W.K.
 Sung, J.J.Y. *see* Wu, J.C.Y.
surgery, 27
 Suyenobu, B. *see* Mayer, E.A.
 Suzuki, H. *see* Suzuki, M.
 Suzuki, K. *see* Suzuki, M.
 Suzuki, M., Suzuki, H., Kitahora, T., Miyazawa, M., Nagahashi, S., Suzuki, K. & Ishii, H. Treatment with a proton pump inhibitor promotes corpus gastritis in patients with *Helicobacter pylori*-infected antrum-predominant gastritis, 159
 Svedberg, P., Johansson, S., Wallander, M.-A., Hamelin, B. & Pedersen, N.L. Extra-intestinal manifestations associated with irritable bowel syndrome: a twin study, 975
 Svensson, H. *see* Hallert, C.
Sydney system, 1923
symptoms, 735
systematic review, 51, 1689
 Sytgat, G.N.J., Van Nueten, L., Van de Velde, I., Joslyn, A. & Hanauer, S.B. Efficacy and safety of oral ridogrel in the treatment of ulcerative colitis: two multicenter randomized, double-blind studies, 87
 Szeto, M.L. *see* Hung, W.K.
 Szeto, M.L. *see* Yee, Y.K.
 Szilagyi, A. Review article: lactose — a potential prebiotic, 1591
 Takashima, M. *see* Furuta, T.
 Talbot, I.C. *see* Mimura, T.
 Talbot, I.C. *see* Van Den Bogaerde, J.
 Talley, N.J. *see* Eslick, G.D.
 Talley, N.J. *see* Holtmann, G.
 Tami, J. *see* Yacyshyn, B.R.
 Tanaka, S. *see* Ito, M.
 Tang, V.S.Y. *see* Wong, W.M.
 Tang, V.S.Y. *see* Xia, H.H.-X.
 Tarkova, L., Yoncheva, K., Muhtarov, M., Kadyan, H. & Draganov, V. Topical mononitrate treatment in patients with anal fissure, 101
 Tatsuguchi, A. *see* Futagami, S.
 Taupo, T. *see* Verghese, V.J.
 Tchuenbou, J. *see* Gournay, J.
tegaserod, 1701, 1877
 Tejura, B. *see* Warrington, S.
 Tendler, D.A. *see* Spechler, S.J.
 Tessieri, L. *see* Bilardi, C.
 Tessieri, L. *see* Zentilin, P.
 Testa, E. *see* Giannini, E.
 Testa, E. *see* Zentilin, P.
 Testa, R. *see* Giannini, E.
tetracycline, 569, 1457
 Thabut, D. *see* Goulenok, C.
thalidomide, 1117, 2115
therapeutic use, 27
 The Axys Ulcerative Colitis Study Group, *see* Tremaine, W.J.
 The Claoam Study Group, *see* Malchow, H.
 The European Helicobacter Pylori Study Group (EHPSG), *see* Malfertheiner, P.
 The Group for Eradication Studies from Catalonia, Aragón (GRESCA), *see* Calvet, X.
 The Group d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID), *see* Abitbol, V.
 The Italian Gastric Lymphoma Study Group, *see* Caletti, G.
 The Pantoprazole US GERD Study Group B, *see* Kovacs, T.O.G.

the rhIL-11 Crohn's Study Group. *see* Sands, B.E.

Therapondos, G. *see* Tripathi, D.

therapy. 1, 527

thiopurine methyltransferase activity, 389

thiopurine methyltransferase, 79, 1743

thiopurines, 1831

Thomas, C. *see* Massironi, S.

Thomas, G.A.O. *see* Hawkes, N.D.

Thomforde, G. *see* Kuo, B.

Thompson Coon, J. & Ernst, E. Systematic review: herbal medicinal products for non-ulcer dyspepsia, 1689

Thompson, B.F., Arguedas, M.R. & Wilcox, C.M. Antibiotic prophylaxis prior to endoscopic retrograde cholangiopancreatography in patients with obstructive jaundice: is it worth the cost?, 727

Thompson, W.G. *see* Camilleri, M.

Thompson, W.G. Review article: the treatment of irritable bowel syndrome, 1395

Thomson, A.B.R. *see* Huang, J.-Q.

thoracic and lumbar spine, 1519

Thornton, P.C. *see* Green, J.R.B.

Thornton, P.C. *see* Mansfield, J.C.

three-day rule, 1011

thromboxane, 1683

tinidazole, 145

Tinto, A., Lloyd, D.A.J., Kang, J.-Y., Majeed, A., Ellis, C., Williamson, R.C.N. & Maxwell, J.D. Acute and chronic pancreatitis—diseases on the rise: a study of hospital admissions in England 1989/90–1999/2000, 2097

Tinto, A. *see* Kang, J.-Y.

Tito, L. *see* Calvet, X.

TLOSR, 1655

T-lymphocytes, 1021

To, K.F. *see* Cheng, A.S.L.

Togliani, T. *see* Caletti, G.

Tolley, K. *see* Klok, R.M.

Tondu, F. *see* Marteau, P.

Tong, T.S.M. *see* Hung, W.K.

Torrente, F. *see* Barabino, A.

Tositti, G. *see* Fabris, P.

Tougas, G., Snape Jr, W.J., Otten, M.H., Earnest, D.L., Langaker, K.-E., Pruitt, R.E., Pecher, E., Nault, B. & Rojavin, M.A. Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome, 1701

toxicity, 1743

toxicity prognosis, 707

TPMT, 1743

transient lower oesophageal sphincter relaxation, 17, 743

transit, 603

Travis, S. *see* Fraser, A.G.

treatment, 683, 1047, 1125, 1157, 1407

treatment-response, 1641

Treem, W.R. *see* Orenstein, S.R.

Tremaine, W. *see* Kane, S.V.

Tremaine, W.J., Brzezinski, A., Katz, J.A., Wolf, D.C., Fleming, T.J., Mordenti, J., Strenkoski-Nix, L.C., Kurth, M.C. & the Axys Ulcerative Colitis Study Group. Treatment of mildly to moderately active ulcerative colitis with a tryptase inhibitor (APC 2059): an open-label pilot study, 407

Triadaflopoulos, G. *see* Passaro, D.J.

Triantafyllou, K. *see* Georgopoulos, S.D.

triglycerides, 577

Trimbath, J.D. & Giardiello, F.M. Review article: genetic testing and counselling for hereditary colorectal cancer, 1843

Tripathi, D., Therapondos, G., Lui, H.F., Stanley, A.J. & Hayes, P.C. Haemodynamic effects of acute and chronic administration of low-dose carvedilol, a vasodilating β -blocker, in patients with cirrhosis and portal hypertension, 373

triple eradication therapy, 1933

triple therapy, 137, 145, 153, 1149, 1261, 1669, 2107

Trotter, J.F. *see* Hayashi, P.H.

tryptase inhibitor, 407

Tsiaoussis, J. *see* Athanasakis, E.

Tsukui, T. *see* Futagami, S.

Tu, T.-C. *see* Liao, C.-C.

Tuleu, C., Basit, A.W., Waddington, W.A., Ell, P.J. & Newton, J.M. Colonic delivery of 4-aminosalicylic acid using amylose–ethylcellulose-coated hydroxypropylmethylcellulose capsules, 1771

tumour necrosis factor α , 2115

Tura, S. *see* Caletti, G.

Tutuian, R., Katz, P.O., Ahmed, F., Korn, S. & Castell, D.O. Over-the-counter H₂-receptor antagonists do not compromise intragastric pH control with proton pump inhibitors, 473

Tutuian, R., Katz, P.O., Bochenek, W. & Castell, D.O. Dose-dependent control of intragastric pH by pantoprazole, 10, 20 or 40 mg, in healthy volunteers, 829

twins, 975

Tytgat, G. *see* Malfertheiner, P.

Tytgat, G.N.J. *see* Hirsch, D.P.

Tytgat, G.N.J. *see* Kuiken, S.D.

ulceration, 1917

ulcerative colitis, 27, 61, 69, 87, 197, 207, 325, 407, 693, 699, 919, 1109, 1125, 1225, 1233, 1743, 1751, 1889, 1895, 2061

Ullerich, H., Avenhaus, W., Poremba, C., Domschke, W. & Menzel, J. High-dose interferon α -2a with ribavirin and amantadine in naïve chronic hepatitis C patients — results of a randomized, prospective, pilot study, 2107

ultrasonography, 129

upper gastrointestinal bleeding, 497

upper gastrointestinal endoscopy, 105, 111

upper gastrointestinal malignancies, 1011

urea breath test, 137, 1443, 1733

Usadel, K.-H. *see* Braden, B.

Vaira, D. *see* Palli, D.

Vaira, D. *see* Voland, P.

Vaizey, C.J. *see* Van Den Bogaerde, J.

Vakil, N., Rydén-Bergsten, T. & Bergenheim, K. Systematic review: patient-centred endpoints in economic evaluations of gastro-oesophageal reflux disease. 1469

Valdimarsson, T. *see* Hallert, C.

Valero, C. *see* Calvet, X.

Vallve, M., Vergara, M., Gisbert, J.P. & Calvet, X. Single vs. double dose of a proton pump inhibitor in triple therapy for *Helicobacter pylori* eradication: a meta-analysis. 1149

Valpiani, D. *see* Rizzello, F.

Van Acker, K.L. *see* De Block, C.E.M.

van Balkom, B.P.J., Schoon, E.J., Stockbrügger, R.W., Wolters, F.L., van Hogezand, R.A., van Deventer, S.J.H., Oldenburg, B., van Dullemen, H.M. & Russel, M.G.V.M. Effects of anti-tumour necrosis factor- α therapy on the quality of life in Crohn's disease. 1101

Van Berge Henegouwen, G.P. *see* Clemens, C.H.M.

Van De Castele, M., Zaman, Z., Zeegers, M., Servaes, R., Fevery, J. & Nevens, F. Blood antioxidant levels in patients with alcoholic liver disease correlate with the degree of liver impairment and are not specific to alcoholic liver injury itself. 985

Van de Velde, I. *see* Sytgat, G.N.J.

van den Berg, P.B. *see* Klok, R.M.

Van Den Bogaerde, J., Cahill, J., Emmanuel, A.V., Vaizey, C.J., Talbot, I.C., Knight, S.C. & Kamm, M.A. Gut mucosal response to food antigens in Crohn's disease. 1903

van Deventer, S.J.H. *see* van Balkom, B.P.J.

van Dullemen, H.M. *see* van Balkom, B.P.J.

Van Gaal, L.F. *see* De Block, C.E.M.

Van Haarst, A.D. *see* Kamerling, I.M.C.

Van Hecken, A., Juliano, M.L., De Peleire, I., Arnout, J., Dynder, A., Wildonger, L., Petty, K.J., Gottesdiener, K. & De Hoon, J.N. Effects of enteric-coated, low-dose aspirin on parameters of platelet function. 1683

Van Herwaarden, M.A., Samson, M., Rydholm, H. & Smout, A.J.P.M. The effect of baclofen on gastro-oesophageal reflux, lower oesophageal sphincter function and reflux symptoms in patients with reflux disease. 1655

van Hogezand, R.A. *see* van Balkom, B.P.J.

Van Hoof, V. *see* De Block, C.E.M.

Van Marck, E.A.E. *see* De Block, C.E.M.

Van Nueten, L. *see* Sytgat, G.N.J.

Van Oene, J.C. *see* Sloots, C.E.J.

Van Rossum, L.G.M. *see* Laheij, R.J.F.

Van Vlierberghe, H., Verdieuvel, H., Colle, I., Delanghe, J., Praet, M., Bernard, D., Leroux-Roels, G. & De Vos, M. Non-transferrin-bound iron in untreated and ribavirin-treated chronic hepatitis C patients. 1555

Vanasia, M. *see* Distrutti, E.

Vanheuverzwijn, R. *see* Dewit, O.

Varga, L. *see* Netzer, P.

Varoli, G. *see* Rizzello, F.

Veitch, A. *see* Zulu, I.

Veldhuyzen van Zanten, S.J.O. *see* Malfertheiner, P.

Ventura, A. *see* Barabino, A.

Verdieuvel, H. *see* Van Vlierberghe, H.

Vergara, M. *see* Vallve, M.

Verghese, V.J., Ayub, K., Qureshi, W., Taupo, T. & Graham, D.Y. Low-salt bowel cleansing preparation (LoSo Prep) as preparation for colonoscopy: a pilot study. 1327

Verlinden, M.H. *see* Chen, C.L.

Verspaget, H.W. *see* Kruidenier, L.

Vigneri, S. *see* Bilardi, C.

Vigneri, S. *see* Zentilin, P.

Vilei, M.T. *see* Pazzi, P.

Villarejo, J. *see* Sabate, J.M.

Viramontes, B. *see* Kuo, B.

visceral pain. 1357

Viscido, A. *see* Caprilli, R.

vitamin D. 1919

vitamin intake. 1333

Vogt, B. *see* Mayer, E.A.

Voland, P., Weeks, D.L., Vaira, D., Prinz, C. & Sachs, G. Specific identification of three low molecular weight membrane-associated antigens of *Helicobacter pylori*. 533

Von Arnim, U. *see* Peitz, U.

Wada, K. *see* Futagami, S.

Waddington, W.A. *see* Tuleu, C.

Wai, C.T. *see* Lim, L.L.

Wakefield, A.J., Puleston, J.M., Montgomery, S.M., Anthony, A., O'Leary, J.J. & Murch, S.H. Review article: the concept of entero-colonic encephalopathy, autism and opioid receptor ligands. 663

Wallander, M.-A. *see* Svedberg, P.

Wang, W.-C. *see* Poon, S.K.

Wang, W.H. *see* Wong, W.M.

Wang, Y.-L. *see* Sheu, B.-S.

Ward, E.M. & Wolfsen, H.C. Review article: the non-inherited gastrointestinal polyposis syndromes. 333

Warrington, S., Baisley, K., Boyce, M., Tejura, B., Morocutti, A. & Miller, N. Effects of rabeprazole, 20 mg, or esomeprazole, 20 mg, on 24-h intragastric pH and serum gastrin in healthy subjects. 1301

Watanabe, H. *see* Rugge, M.

Watts, D. *see* Arnott, I.D.R.

Weeks, D.L. *see* Voland, P.

Weir, D.G. *see* Mahmud, N.

Whitman, R. *see* Pehlivanov, N.

Whittington, C.A. & Kowdley, K.V. Review article: haemochromatosis 1963

Wicks, A.C. *see* Khan, Z.

Wicks, A.C.B. *see* Massironi, S.

Wienbeck, M. *see* Hallerbäck, B.

Wilcox, C.M. *see* Kovacs, T.O.G.

Wilcox, C.M. *see* Thompson, B.F.

Wildi, S. *see* Netzer, P.

Wildonger, L. *see* Van Hecken, A.

Wilkins, R. *see* Sands, B.E.

Williamson, R.C.N. *see* Tinto, A.

Winston, B.D. *see* Sands, B.E.

Wolf, D.C. *see* Tremaine, W.J.

Wolfsen, H.C. *see* Ward, E.M.

Wolle, K. *see* Peitz, U.

Wolters, F.L. *see* van Balkom, B.P.J.

Wong, B.C.Y. *see* Hu, W.H.C.

Wong, B.C.Y. *see* Hung, W.K.

Wong, B.C.Y. *see* Ng, F.H.

Wong, B.C.Y. *see* Wong, W.-M.

Wong, B.C.Y. *see* Wong, W.M.

Wong, B.C.Y. *see* Xia, H.H.-X.

Wong, G.S.W. *see* Hung, W.K.

Wong, S.K.H. *see* Wu, J.C.Y.

Wong, S.W. *see* Yee, Y.K.

Wong, S.Y. *see* Ng, F.H.

Wong, T. *see* Lamb, E.J.

Wong, W.-M., Lai, K.C., Lau, C.P., Hu, W.H.C., Chen, W.H., Wong, B.C.Y., Hui, W.M., Wong, Y.H., Xia, H.H.X. & Lam, S.K. Upper gastrointestinal evaluation of Chinese patients with non-cardiac chest pain, 465

Wong, W.-M., Lam, S.K., Hui, W.M., Lai, K.C., Chan, C.K., Hu, W.H.C., Xia, H.H.X., Hui, C.K., Yuen, M.F., Chan, A.O.O. & Wong, B.C.Y. Long-term prospective follow-up of endoscopic oesophagitis in southern Chinese — prevalence and spectrum of the disease, 2037

Wong, W.M., Wong, B.C.Y., Lu, H., Gu, Q., Yin, Y., Wang, W.H., Fung, F.M.Y., Lai, K.C., Xia, H.H.X., Xiao, S.D. & Lam, S.K. One-week omeprazole, furazolidone and amoxicillin rescue therapy after failure of *Helicobacter pylori* eradication with standard triple therapies, 793

Wong, W.M., Wong, B.C.Y., Xia, H.H.X., Tang, V.S.Y., Lai, K.C., Hu, W.H.C., Yuen, M.F., Chan, C.K. & Lam, S.K. An evaluation of a rapid urine test for the diagnosis of *Helicobacter pylori* infection in the Chinese population, 813

Wong, W.-M. *see* Hu, W.H.C.

Wong, W.-M. *see* Hui, C.-K.

Wong, W.M. *see* Hung, W.K.

Wong, W.M. *see* Ng, F.H.

Wong, W.M. *see* Xia, H.H.-X.

Wong, Y.H. *see* Wong, W.-M.

Wood, M. *see* Malik, A.H.

Woolner, J. *see* Middleton, S.J.

Wrangstadh, M. *see* Malfertheiner, P.

Wright, N.A. *see* Khan, Z.

Wright, N.A. *see* Sasaki, M.

Wruble, L. *see* Sands, B.E.

Wu, C.-H. *see* Liao, C.-C.

Wu, H.-W. *see* Sheu, B.-S.

Wu, J.C.Y., Chan, F.K.L., Wong, S.K.H., Lee, Y.T., Leung, W.K. & Sung, J.J.Y. Effect of *Helicobacter pylori* eradication on oesophageal acid exposure in patients with reflux oesophagitis, 545

Wu, J.-J. *see* Sheu, B.-S.

Xia, H.H.-X., Wong, B.C.Y., Wong, W.M., Tang, V.S.Y., Cheung, H.K.L., Sham, F.N.F., Fung, F.M.Y., Lai, K.C., Hu, W.H.C., Chan, C.K. & Lam, S.K. Optimal serological tests for the detection of *Helicobacter pylori* infection in the Chinese population, 521

Xia, H.H.-X. *see* Eslick, G.D.

Xia, H.H.X. *see* Hung, W.K.

Xia, H.H.X. *see* Wong, W.-M.

Xia, H.H.X. *see* Wong, W.M.

Xia, H.X.H. *see* Hu, W.H.C.

Xiao, F. *see* Furuta, T.

Xiao, F. *see* Shirai, N.

Xiao, S.D. *see* Wong, W.M.

Xynos, E. *see* Athanasakis, E.

Yacyshyn, B.R., Barish, C., Goff, J., Dalke, D., Gaspari, M., Yu, R., Tami, J., Dorr, F.A. & Sewell, K.L. Dose ranging pharmacokinetic trial of high-dose alicaforse (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease, 1761

Yan, P. *see* Eslick, G.D.

Yang, C.C. *see* Poon, S.K.

Yang, H.-B. *see* Sheu, B.-S.

Yang, U.S. *see* Choi, I.J.

Yarbrough, K. *see* Malik, A.H.

Yee, Y.K., Yip, K.T., Que, T.L., Chang, K.K., Li, K.F., Lee, C.K., Wong, S.W., Lau, S.F. & Szeto, M.L. Efficacy of enzyme immunoassay for the detection of *Helicobacter pylori* antigens in frozen stool specimens: local validation, 1739

Yim, A. *see* Ansari, A.

Yin, Y. *see* Wong, W.M.

Yip, A.W.C. *see* Hung, W.K.

Yip, K.T. *see* Yee, Y.K.

yogurt, 1669

Yoncheva, K. *see* Tankova, L.

Yoshihara, M. *see* Ito, M.

Yoshikawa, I., Murata, I., Kume, K., Kanagawa, K., Hirohata, Y., Nakamura, H. & Otsuki, M. Serum pepsinogen can predict response to H₂-receptor antagonist in patients with functional dyspepsia, 1805

You, J.H.S., Lee, K.K.C., Chan, T.Y.K., Lau, W.H. & Chan, F.K.L. Arthritis treatment in Hong Kong — cost analysis of celecoxib versus conventional NSAIDS, with or without gastroprotective agents, 2089

Yu, R. *see* Yacyshyn, B.R.

Yuen, M.-F. *see* Hui, C.-K.

Yuen, M.F. *see* Hung, W.K.

Yuen, M.F. *see* Wong, W.-M.

Yuen, M.F. *see* Wong, W.M.

Yuen, W.C. *see* Ng, F.H.

Yuki, M. *see* Adachi, K.

Zagari, R.M. *see* Bazzoli, F.

Zaman, Z. *see* Van De Castele, M.

Zambia, 595

Zar, S., Benson, M.J. & Kumar, D. Review article: bloating in functional bowel disorders, 1867

Zeegers, M. *see* Van De Castele, M.

Zeijlon, L. *see* Malfertheiner, P.

Zentilin, P., Conio, M., Mele, M.R., Mansi, C., Pandolfo, N., Dulbecco, P., Gambaro, C., Tessieri, L., Iritano, E., Bilardi, C., Biagini, R., Vigneri, S. & Savarino, V. Comparison of the main oesophageal pathophysiological characteristics between short- and long-segment Barrett's oesophagus, 893

Zentilin, P., Seriolo, B., Dulbecco, P., Caratto, E., Iiritano, E.,
Fasciolo, D., Bilardi, C., Mansi, C., Testa, E. & Savarino, V.
Eradication of *Helicobacter pylori* may reduce disease severity in
rheumatoid arthritis. 1291

Zentilin, P. *see* Bilardi, C.

Zinicola, R. *see* Falasco, G.

Zinzani, P.L. *see* Caletti, G.

Zocco, M.A. *see* Armuzzi, A.

Zocco, M.A. *see* Di Caro, S.

Zollinger-Ellison syndrome. 1367

Zoras, O.J. *see* Athanasakis, E.

Zulu, I., Veitch, A., Sianongo, S., McPhail, G., Feakins, R.,
Farthing, M.J.G. & Kelly, P. Albendazole chemotherapy for
AIDS-related diarrhoea in Zambia — clinical, parasitological
and mucosal responses. 595

